CONFIDENTIAL  VP-C21-008 Version 5.0 
13-Apr-2022  Page 1 of 77 Vicore Pharma AB   
 
Clinical Trial Protocol  
 
 
Protocol Number:  VP-C21-008 
Title:  A randomized, double -blind, placebo -controlled,  parallel 
group,  phase  3, multicenter  trial investigating the efficacy and safety 
of C21 as add on to standard of care in adult subjects  with COVID -19. 
Brief Title : A trial to investigate recovery from COVID -19 with C21  in adult 
subjects  
Acronym : ATTRACT -3 
Trial Phase : 3 
Compound : C21 (Compound 21)  
Version:  5.0 
Sponsor:  Vicore Pharma AB  
Kronhusgatan [ADDRESS_312246] Information  
 
The Principal Investigators (PIs) are responsible for ensuring that procedures and expertise are 
available to handle any potential medical emergencies occurring during the trial. A medical 
emergency usually constitutes a serious adverse event (SAE) and is to be reported as such. 
Detailed SAE reporting procedures are described in Section 8.5.  
The Sponsor CRO  provides a 24 -hour, 7-days a week (24/7)  phone service for all active sites , 
their PI s and site support staff for urgent cases.  24/[ADDRESS_312247] information:  
Region  Phone  Fax E-mail 
North America 
and South 
America  +[PHONE_5343] (toll -free)  
+[PHONE_5344] (direct)  +[PHONE_5345] (toll -free)  
+[PHONE_5346] (direct)  C21008 -[EMAIL_4951]  
 
Europe, Asia -
Pacific  and 
Africa + 49 [PHONE_5347]  + 44 [PHONE_5348]  
 
CONFIDENTIAL  VP-C21-008 Version 5.0 
13-Apr-2022  Page 3 of 77 Vicore Pharma AB  Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ .......... 6 
1.1. Synopsis  ................................ ................................ ................................ ............................ 6 
1.2. Schema  ................................ ................................ ................................ .............................. 9 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 10 
2. Introduction  ................................ ................................ ................................ ................... 11 
2.1. Trial Rationale  ................................ ................................ ................................ ................ 11 
2.2. Background  ................................ ................................ ................................ ..................... 11 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ [ADDRESS_312248] Administered  ................................ ........................... 25 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 25 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ [ADDRESS_312249] Discontinuation/Withdrawal  ................................ ................................ .......... [ADDRESS_312250] Discontinuation/Withdrawal from the Trial  ................................ ...................... [ADDRESS_312251] to Follow up  ................................ ................................ ................................ ............ 30 
8. Trial Assessments and Procedures  ................................ ................................ .............. 31 
8.1. Screening Assessments  ................................ ................................ ................................ ...31 
8.1.1.  Demographics  ................................ ................................ ................................ ................. 31 
8.1.2.  Medical History  ................................ ................................ ................................ .............. 31 
CONFIDENTIAL  VP-C21-008 Version 5.0 
13-Apr-2022  Page 4 of 77 Vicore Pharma AB  8.2. Efficacy Assessments  ................................ ................................ ................................ .....32 
8.2.1.  8-point Ordinal Scale  ................................ ................................ ................................ ......32 
8.2.2.  Supplemental Oxygen  ................................ ................................ ................................ .....32 
8.2.3.  Oxygen Saturation  ................................ ................................ ................................ .......... 33 
8.3. Survival and Hospi[INVESTIGATOR_059]  ................................ ................................ ........................... 33 
8.4. Safety Assessments  ................................ ................................ ................................ ......... 33 
8.4.1.  Physical Examinations  ................................ ................................ ................................ ....33 
8.4.2.  Vital Signs  ................................ ................................ ................................ ....................... 33 
8.4.3.  Electrocardiograms  ................................ ................................ ................................ ......... 34 
8.4.4.  Clinical Safety Laboratory Tests  ................................ ................................ .................... 34 
8.4.5.  Hepatic Impairment  ................................ ................................ ................................ ........ 35 
8.4.6.  Pregnancy Testing  ................................ ................................ ................................ ........... 36 
8.4.7.  SARS -CoV -2 Variant  ................................ ................................ ................................ .....37 
8.4.8.  New Infections  ................................ ................................ ................................ ................ 37 
8.5. Adverse Events, Serious Adverse Events, and Other Safety 
Reporting  ................................ ................................ ................................ ........................ 37 
8.5.1.  Time Period and Frequency for Collecting AE and SAE 
Information  ................................ ................................ ................................ ..................... 37 
8.5.2.  Method of Detecting AEs and SAEs  ................................ ................................ .............. 37 
8.5.3.  Follow -up of A es and SAEs  ................................ ................................ ........................... 38 
8.5.4.  Regulatory Reporting Requirements for SAEs  ................................ ............................... 38 
8.5.5.  Pregnancy  ................................ ................................ ................................ ........................ 38 
8.6. Pharmacokinetics  ................................ ................................ ................................ ............ 39 
8.7. Genetics  ................................ ................................ ................................ .......................... 39 
8.8. Biomarkers  ................................ ................................ ................................ ...................... 39 
8.9. Immunogenicity Assessments ................................ ................................ ......................... 40 
8.10.  Health Economics OR Medical Resource Utilization and Health 
Economics  ................................ ................................ ................................ ....................... 40 
9. Statistical Considerations  ................................ ................................ ............................. 41 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....41 
9.1.1.  Multiplicity Adjustment  ................................ ................................ ................................ ..41 
9.2. Analysis Sets  ................................ ................................ ................................ ................... 41 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 42 
9.3.1.  General Considerations  ................................ ................................ ................................ ...42 
9.3.2.  Primary Endpoint/Estimand Analysis  ................................ ................................ ............. 42 
9.3.3.  Secondary Endpoints Analysis  ................................ ................................ ....................... 43 
9.3.4.  Exploratory Endpoint Analysis  ................................ ................................ ....................... 44 
9.3.5.  Safety Analyses  ................................ ................................ ................................ ............... 45 
9.3.6.  Other Analyses  ................................ ................................ ................................ ................ 45 
9.4. Interim Analysis  ................................ ................................ ................................ .............. 46 
9.5. Sample Size Determination  ................................ ................................ ............................ 46 
10. Supporting Documentation and Operational Considerations  ................................ ..47 
10.1.  Appendix 1: Regulatory, Ethical, and Trial Oversight 
Considerations  ................................ ................................ ................................ ................ 47 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 47 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 47 
CONFIDENTIAL  VP-C21-008 Version 5.0 
13-Apr-2022  Page 5 of 77 Vicore Pharma AB  10.1.3.  Informed Consent Process  ................................ ................................ .............................. 47 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 48 
10.1.5.  Committees Structure ................................ ................................ ................................ ......48 
10.1.6.  Dissemination of Clinical Trial Data  ................................ ................................ .............. 48 
10.1.7.  Data Quality Assurance  ................................ ................................ ................................ ..49 
10.1.8.  Source Documents  ................................ ................................ ................................ .......... 49 
10.1.9.  Trial and Site Start and Closure  ................................ ................................ ...................... 50 
10.1.10.  Publication Policy  ................................ ................................ ................................ ........... 51 
10.2.  Appendix 2: A Es and SAEs: Definiti ons and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ ......................... 52 
10.2.1.  Definition of AE  ................................ ................................ ................................ ............. 52 
10.2.2.  Definition of SAE  ................................ ................................ ................................ ........... 53 
10.2.3.  Recording and Follow -Up of AE and/or SAE  ................................ ................................ 54 
10.2.4.  Reporting of SAEs  ................................ ................................ ................................ .......... 56 
10.3.  Appendix 3: Contraceptive and Barrier Guidance  ................................ .......................... [ADDRESS_312252] of Care for COVID -19 ................................ ................................ .61 
10.5.  Appendix 5: Country -specific Requirements  ................................ ................................ .62 
10.5.1.  India  ................................ ................................ ................................ ................................ 62 
10.6.  Appendix 6: Abbreviations  ................................ ................................ ............................. 63 
11. Protocol Amendment History  ................................ ................................ ...................... 66 
12. References  ................................ ................................ ................................ ...................... 74 
13. Sponsor and Coordinating Investigator [INVESTIGATOR_256925]  ................................ .................. 77 
 
CONFIDENTIAL  VP-C21-008 Version 5.0 
13-Apr-2022  Page 6 of 77 Vicore Pharma AB  1. Protocol Summary  
1.1. Synopsis  
Protocol Title:  A randomized, double -blind, placebo -controlled,  parallel group,  phase  3, 
multicenter  trial investigating the efficacy and safety of  C21 as add on to standard of 
care in adult subjects  with COVID -19. 
Brief  Title:  A trial to investigate recovery from COVID -19 with C21 in adult subjects . 
Rationale : The corona virus disease 2019 ( COVID -19) is an ongoing pandemic caused by 
[CONTACT_11550][INVESTIGATOR_82479] 2 (SARS -CoV -2). Although several therapeutic 
agents have been evaluated for the treatment of COVID -19, the morbidity and mortality are still 
significant. The need for safe, effective,  and convenient COVID -[ADDRESS_312253] of care  (SoC) , reduced the need for extended oxygen supplementation and had a  
favorable  benefit/risk profile . The rationale for conducting this phase 3 trial is to confirm the 
efficacy of C21 in subjects with COVID -19. 
Objectives , Endpoint s and Estimands : 
 
Objectives  Endpoints  
Primary   
• Evaluate  the efficacy of  C21 versus 
placebo as add on to SoC  on recovery  
in subjects with  COVID -19. •  All-cause  mortality  up to Day 60. 
Key s econdary    
 • Time  to sustained  hospi[INVESTIGATOR_256926] 60. 
• Supplemental oxygen free days up to 
Day 29.  
• Proportion of subjects free of 
respi[INVESTIGATOR_1399], defined as an 8 -
point ordinal scale score ≤5, at Day 
15. 
• Proportion of subjects discharged 
from hospi[INVESTIGATOR_256927] 15.  
Secondary   
CONFIDENTIAL  VP-C21-008 Version 5.0 
13-Apr-2022  Page 7 of 77 Vicore Pharma AB  • Evaluate the safety profile of C21 
versus placebo as add on to SoC in 
subjects with COVID -19. • Adverse events (AE )s. 
• Serious AEs (SAE )s. 
• Changes in safety laboratory 
assessments . 
• Withdrawals due to A Es. 
• Characterize  the PK profile of C21 in 
subjects  with C OVID -19. • PK parameters . 
• Evaluate the efficacy profile of C21 
versus placebo as add on to SoC in 
subjects with COVID -19. • Proportion  of subjects  discharged  
from  hospi[INVESTIGATOR_256928] 8, 22 and 29. 
• Proportion  of hospi[INVESTIGATOR_256929]-invasive,  invasive  mechanical  
ventilation , extra  corpor eal membrane 
oxygenation  (ECMO ) or supplemental  
oxygen  use at Days 8, 15, 22, 29 and 
60. 
• Proportion of subjects in each 
category  of the 8 -point ordinal scale  at 
Days 8, 15 , 22, 29 and 60 . 
• Duration of hospi[INVESTIGATOR_059] , including 
re-hospi[INVESTIGATOR_059], up to Day 60. 
• Proportion of subjects needing 
intensive care unit stay at Day s 8, 15, 
22, 29 and 60 . 
• Duration of intensive care unit stay, 
including re -admission , up to Day 60. 
• Proportion of subjects on  invasive 
mechanical ventilation or ECMO at 
Days 8, 15 , 22, 29 and 60 , and 
duration of  use up to Day 60.  
• Proportion of subjects free of  
respi[INVESTIGATOR_256930] 8,  22, 29 
and 60 , and r espi[INVESTIGATOR_256931] 60. 
• All-cause mortality up to Days 8, 15 , 
22 and 29.  
• Change from baseline in peripheral 
capi[INVESTIGATOR_19365] (SpO 2) / 
CONFIDENTIAL  VP-C21-008 Version 5.0 
13-Apr-2022  Page 8 of 77 Vicore Pharma AB  fraction of inspi[INVESTIGATOR_1401] (Fi O2) at 
Day 15. 
 
Exploratory   
• To explore the effect of C21 versus 
placebo as add on to SoC on 
inflammation.  • Change from baseline in CRP  at Day 
15. 
• To explore the effect of C21 versus 
placebo as add on to SoC on lung 
injury . • Change from baseline in lactate 
dehydrogenase ( LDH ) at Day 15 . 
 
Primary Estimand :  
All-cause mortality up to Day [ADDRESS_312254] s with no 
confirmed death before or at Day 60 being censored at day  of withdrawal/ Day [ADDRESS_312255] ratio with 95% confidence intervals . 
Overall Design : 
This trial is a randomized,  double -blind, placebo -controlled, parallel -group, [ADDRESS_312256] s, 150 per arm ( oral C21 100 mg twice a day 
(b.i.d. ) or placebo  for 14 days ) according to the 1:1 randomization.  
Randomi zation will be stratified by:  
• Disease severity  (8-point ordinal scale score at Day 1 , score 5 or 6). 
• Region  (North America, South  and Central  America, Europe,  Africa,  or Asia) . 
Approximately [ADDRESS_312257] ( IMP) treatment . 
An independent data monitoring  committee  (DMC) will  review unblinded safety data from the 
trial after data collection for at least [ADDRESS_312258] 150 randomized subjects . In addition, the 
DMC members may call for an ad hoc  safety review meeting at any time during the trial.  
The trial consists of 3 consecutive periods:  a screening period of up to [ADDRESS_312259] IMP intake . Daily visits  are 
required until discharge.  Discharged subjects will return to the clinic for the Day 15 visit. Days 
8, 22, 29 and 60  visits  will be conducted as phone  or video  visits for discharged subjects . 
All subjects will undergo a series of efficacy, safety, and laboratory assessments. Safety 
laboratory tests and samples for future exploratory analysis  will be obtained at the screening 
CONFIDENTIAL  VP-C21-008 Version 5.0 
13-Apr-2022  Page 9 of 77 Vicore Pharma AB  visit, Day 1 (prior to treatment ) and Days 3, 5, [ADDRESS_312260]’s  last follow -up visit.  
The primary endpoint in the trial is all-cause mortality up to Day 60 . 
The key secondary endpoint s are time to sustained hospi[INVESTIGATOR_256932] 60 , supplemental  
oxygen free days up to Day 29,  the proportion of subjects free of respi[INVESTIGATOR_256933] 15 . 
Type 1 errors will be control led using a fixed sequential testing hierarch y. 
1.2. Schema  

CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 10 of 77 Vicore Pharma AB  1.3. Schedule of Activities  (SoA)  
  Screening  IMP Treatment  Period  In-patient   
Stay1)  Follow -up Period2) Unsche -
duled3) 
Visit V1 V2 V3-151) 4) V164) EWD5) V17-29 V30 V31 V32 UV 
Day ( Visit window ) Up to 48h 
prior to V2  Day 1  Days  
2-14 Day 15  
(+1 day)  Days   
16-28  Day 22  
(±1 days)  Day 29  
(±1 days) Day 60 
(±3 days)   
Eligibility/General  
Informed  consent   X           
Eligibility  criteria   X x6)         
Demographics   X           
Medical  history   X            
IMP and Concomitant Therapy  
Randomization     x             
IMP administration7)    x x         (x) 
Check of fasting  criteria     x x         (x) 
IMP accountability       x8) x x        
Previous and 
concomitant  therapy   X x x x x x x x  (x) 
Trial Assessments and Procedures   
8-point  ordinal  scale   X x x x x x x x x (x) 
Supplemental O 2 X x x x x x x x  (x) 
Oxygen saturation  X x x x x x    (x) 
Hospi[INVESTIGATOR_059]  X x x x x x x x x (x) 
Physical  examination  X   x x      (x) 
Body  weight  and height  X               
Vital  signs   X x x x x x     (x) 
12-lead ECG9)  X             (x) 
Adverse  events   X x x x x x x x x10) x 
Biochemistry11) X x12) Days 3, 5, 8, 11 
(all ± 1 day)  x x      (x) 
Haematology11) X x12) Days 3, 5, 8, 11 
(all ± 1 day)  x x      (x) 
Urinanalysis11) X x12)  x x      (x) 
Pregnancy  testing 13) X     x x       (x) 
Oropharyngeal swab   x         
Pharmacokinetics14)  x         
Blood sample for future 
exploratory analysis    x12)   x x        
 
1. Daily visits until discharge.  Visits will be re -initiated in case of a COVID -19 related hospi[INVESTIGATOR_134577] -admission.  
2. Follow -up visits by [CONTACT_630] . 
3. Assessments marked  with () will be performed per investigator judgment  at e.g., COVID -[ADDRESS_312261] is discharged before  Day 8 , the Day 8 visit will be done by [CONTACT_256982] . Site assessments e.g., oxygen saturation , vital signs  and blood sampling  will not be performed . 
5. An early withdrawal (EWD) visit should be performed for subjects withdrawn from the trial prior to Day 15 (Visit 16).  
6. Re-evaluation of eligibility including evaluation of electro cardiogram ( ECG ) and laboratory results from  screening . 
7. IMP is administered b.i.d. from Day s 1 to 14.  
8. IMP accountability will be performed at hospi[INVESTIGATOR_2345].  
9. A historical 12 -lead ECG  is accept able. The ECG should be  ≤2 days old at the time of screening ( Visit 1 ). 
10. SAEs only.   
11. Blood samples taken at screening  will be analyzed locally. Samples taken at Days 1 to 15 , or at the EWD  visit will be analyzed  at a 
central laboratory  (if needed due to  special circumstances e.g. delays in turn -around time due to COVID -19, blood samples may be 
analyzed locally after sponsor approval ). Days 3,  5, [ADDRESS_312262] . 
14. Pharmacokinetic  (PK)  samples will be collected in a subgroup of approximately [ADDRESS_312263] -in-class, low molecular weight, orally available , potent , and selective angiotensin  II 
type 2 receptor (AT2R) agonist being developed for treatment of COVID -[ADDRESS_312264] been evaluated for the treatment of COVID -19, the 
morbidity and mortality are still significant, and the need for safe, effective, and convenient 
COVID -19 drugs is likely to remain even aft er the launch of vaccine programs.  
The recently completed phase 2 trial in hospi[INVESTIGATOR_256934] s with COVID -19 (VP-C21-006) 
showed that C21 on to p of standard of care significantly reduced the need for extended oxygen 
supplementation and had a favorable benefit/risk profile. The rationale for conducting this phase 
[ADDRESS_312265] cases reported in December 2019 (Lu et al., 
2020 ; Wu et al., 2020 ; Zhou et al., 2020 ). The disease expanded rapi[INVESTIGATOR_375], and by [CONTACT_11711] 12, 2020, 
COVID -19 was classified as a pandemic by [CONTACT_38375] (WHO). As of 
January 31, 2021, the WHO has reported more that 100 million confirmed cases of COVID -19 
and 2.2 million deaths globally (WHO, 2020a ). 
While most COVID -[ADDRESS_312266] severe cases, mechanical ventilation (Chen et al., 2020 ; 
Ruan et al., 2020 ; Zhou et al., 2020 ). 
Remdesivir and dexamethasone, have shown some impact on disease remission in large 
controlled trials in hospi[INVESTIGATOR_256935] -[ADDRESS_312267] of care  
(Beigel et al., 2020 ; Group et al., 2020 ) in many countries . Despi[INVESTIGATOR_256936], 
the morbidity and mortality in COVID -[ADDRESS_312268] 
being developed for oral treatment of COVID -19 and fibrotic lung diseases  such as idiopathic 
pulmonary fibrosis . 
A detailed description of the chemistry,  pharmacology, efficacy, and safety of C21 is provided in 
the Investigator’s Brochure  (IB). 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 12 of 77 Vicore Pharma AB  C21 has been evaluated  in 3 completed phase 1 trials (C21 -001-16, C21 -002-16 and C21 -003) 
and in 1 recently completed phase 2 trial in subjects with COVID -19 (VP -C21-006). In total, [ADDRESS_312269] 1 dose of C21. Overall, C21 was well tolerated at doses up 
to 100 mg b.i.d. administered for up to 8 days.  
The SARS -CoV -2 virus is known to bind to and enter target cells through angiotensin conv erting 
enzyme (ACE) 2, an integral component of the renin -angiotensin system (RAS) (Zhang et al., 
2020 ). Within the RAS, the Ang ioten sin II type 1 receptor (AT1R) normally mediates the 
classical actions of Angiotensin  II, including constriction of blood vessels, sodium retention and 
cell growth, while abnormal AT1R activation contributes to the pathogenesis of certain 
cardiovascular, renal an d pulmonary diseases (de Man et al., 2012 ; Savoia & Schif frin, 2006 ; 
Sumners et al., 2019 ). Conversely, activation of the AT2R causes dilatation of blood vesse ls and 
inhibition of inflammation and fibrosis, and is considered to be counter -regulatory to the 
negative effects of AT1R activation (Matavelli et al., 2015 ; Sumners et al., 2019 ). 
While the AT2R is only expressed at low levels in most tissues in healthy adults (De Gasparo, 
2002 ; Steckelings et al., 2005 ), it is highly expressed in alveolar type 2 progenitor cells in the 
adult human lung and can be upregulated during repair and regeneration (Akishita et al., 1999 ; 
Protein -Atlas ). This, coupled with the belief that the RAS may play a key role in the 
development of COVID -[ADDRESS_312270] s with COVID -19 were investigated in a randomized, 
double -blind, placebo -controlled, phase 2 trial (VP-C21-006). The trial included [ADDRESS_312271] s hospi[INVESTIGATOR_256937] C OVID -19, having a CRP between 50 -150 mg/L  and not in need of 
mechanical ventilation. The subject s were randomized to receive oral treatment with C21 (100 
mg b.i.d., n=51) or placebo (n=56) for [ADDRESS_312272] (IMP) 
dose.  
The treatment groups were well balanced regarding age (mean 52.6 years) and gender (75.5% 
males). Most patients had one or more coexisting med ical condition s. Hypertension and 
overweight/obe sity were more common in the C21 group compared with the placebo group, but 
there was no dif ference in the presence of diabetes mellitus. Supplementary oxygen supply at 
baseline was needed in 57.5% of the pat ients with no major difference between the treatment 
groups. Concomitant medication according to local standard of care was permitted in the  trial. A 
vast majority of the patients received glucocorticoids, and most patients received antibacterial 
and antiv iral compounds (remdesivir in 67.0%), with no major differences between the treatment 
groups.  
Extended need for oxygen therapy was more frequent in the placebo group than in the C21 
group. At Day 14, only one patient in the C21 group, compared to 11 patien ts in the placebo 
group, needed supplementary oxygen (p=0.003). This difference was already apparent at the end 
of the 7-day treatment period, when 27.5% of patients in the C21 group and 45.5% in the placebo 
group were in need of supplemental oxygen (p=0.0 55). The reduced need for extended oxygen 
supplementation indicates that treatment with C21 improves gas exchange at the alveolar level. 
Considering that the alveolar type 2 progenitor cells  appear to be the only cells in the lungs that 
express the AT2R  (Protein -Atlas ) and are suggested to be the primary site for viral replication in 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 13 of 77 Vicore Pharma AB  the distal airways  (Szekely et al., 2020 ), C21 may restore respi[INVESTIGATOR_256938].  
There were [ADDRESS_312273] 
severe disease (Tan et al., 2020 ; Wang, 2020 ) and mortality (Ruan et al., 2020 ) in COVID -19. 
However, there was a rapid and profound decrease in CRP in both the C21 and the placebo 
group, most l ikely because the patients were treated with glucocorticoids which became part of 
standard of care at the time of trial initiation  likely leading to no statistical difference in the 
primary endpoint CRP . Nevertheless, in the patients with more pronounced r espi[INVESTIGATOR_256939], there was a small but significantly greater 
reduction of CRP in the C21 than in the placebo group . 
There were 64 treatment -emergent AEs reported by 60.8% of the patients in the C21 group and 
90 events reported by 67.3% of the patients in the placebo group. Most events were mild, and no 
event in either group was classified as related to trial treatment by [CONTACT_473]. The most 
frequ ent AE was hyperglycemia, which occurred more frequently in the C21 group than in the 
placebo group. The level of hyperglycemia was predominantly mild and not reported as related 
to C21 by [CONTACT_431] . 
Taken together , C21 on top of standard of care, incl uding glucocorticoids and remdesivir, 
significantly improved respi[INVESTIGATOR_256940] a reduced need for supplemental oxygen 
in hospi[INVESTIGATOR_256941] -19 patients.  
2.3. Benefit/Risk Assessment  
COVID -[ADDRESS_312274] affected bodily 
system . In general, hypoxemia is an accepted indication for intubation in COVID -19 patients  
(Voshaar et al. , 2021 ). The results of the phase 2 trial in patients with COVID -19 (VP-C21-006) 
suggest a clinically relevant beneficial effect on the need for oxygen supplementation at a dose 
of 100  mg b.i.d. Overall , the safety profile of C21 , as available  from pre -clinical and phase 1 and 
2 clinical trial data, is interpreted  as favorable  for the treatment of COVID -19. 
More detailed information about the known and expected benefits and risks , and reasonably 
expected AEs of C21 m ay be found in the IB.  
 
 
 
 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 14 of 77 Vicore Pharma AB  2.3.1.  Risk Assessment  
Potential Risk of 
Clinical Significance  Summary of Data/Rationale 
for Risk   Mitigation Strategy  
IMP - C21 
Alopecia  
 Reversible alopecia was 
observed in subjects who 
received 200 mg b.i.d. for 8 
days in a phase 1 trial, C21 -
003. Alopecia was not 
observed in the VP -C21-006 
trial ([ADDRESS_312275] treated with 
100 mg b.i.d. for 7 days) . 
Further information can be 
found in the IB . No mitigation strategy 
implemented due to the severity 
of the COVID -19 disease in the 
trial population and the low risk 
of developi[INVESTIGATOR_256942] (100 mg b.i.d. for 14 
days).  
Drug -drug interactions  C21 is metabolized primarily 
by [CONTACT_097]3A4 . 
 Exclusion of subjects treated with 
strong  CYP3A4 inducers and/or 
with Warfarin . 
In vitro  data show that a 
clinically relevant i nteraction 
with CYP enzymes (e.g. , 
CYP2C9, CYP3A4 and  
CYP1A2)  and efflux 
transporters ( multi -drug 
resistance gene ( MDR1 ) and 
breast cancer resistance protein  
(BCRP) ) cannot be excluded.  The medical monitor and the 
DMC will monitor the extent of 
co-administration  with CYP1A2, 
CYP3A4 and CYP2C9 substrates 
with a narrow th erapeutic index  
and will inform the investigator if  
sub-optimal combinations occur.  
Exclusion of subjects treated with  
P-gp substrates with narrow 
therapeutic index , high dose 
BCRP sensitive substrates , and 
sulphasalazine or rosuvastatin . 
Drug -food interactions  Exposure of C21 was 
substantially decreased under 
fed conditions as compared to 
fasted conditions indicating an 
interaction with food ( VP-C21-
003). IMP will be administered in 
fasting conditions (see Section  
5.3). 
Correct administration of IMP in 
relation to food intake will be 
monitored during th e trial.  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 15 of 77 Vicore Pharma AB   
2.3.2.  Benefit Assessment  
Up to 20% of symptomatic individuals with COVID -[ADDRESS_312276] significant implications for the 
ability to end this pandemic  (Xie et al., 2 020). 
Subjects randomized to active treatment  in this trial may recover earlier or have a reduced risk of 
developi[INVESTIGATOR_256943] -19 disease . The option for out -patient 
treatment (following hospi[INVESTIGATOR_059]) could reduce  the strain on vital costly hospi[INVESTIGATOR_256944] . 
All subjects will receive regular medical evaluations associated with their participation in the 
trial and will contribute  to the development of new therapi[INVESTIGATOR_14953] a disease area with a high unmet 
need . 
2.3.3.  Overall Benefit Risk Conclusion  
Considering  the measures taken to minimize risk to subject s participating in this trial, the 
potential risks identified in association with C21 are justified by [CONTACT_256983] s with COVID -19. 
 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 16 of 77 Vicore Pharma AB  3. Objectives , Endpoints , and Estimands  
 
 
Objectives  Endpoints  
Primary   
• Evaluate  the efficacy of  C21 versus 
placebo as add on to SoC  on recovery 
in subjects with  COVID -19. • All-cause  mortality  up to Day 60 
Key secondary   
 • Time  to sustained  hospi[INVESTIGATOR_256926] 60. 
• Supplemental oxygen free days up to 
Day 29.  
• Proportion of subjects free of 
respi[INVESTIGATOR_1399], defined as an 8 -
point ordinal scale score ≤5, at Day 
15. 
• Proportion  of subjects  discharged  
from  hospi[INVESTIGATOR_256945] 15. 
Secondary   
• Evaluate the safety profile of C21 
versus placebo as add on to SoC in 
subjects with COVID -19. • AEs. 
• SAE s. 
• Changes in safety laboratory 
assessments.  
• Withdrawals due to AEs.  
• Characterize  the PK profile of C21 in 
subjects  with COVID -19. • PK parameters.  
• Evaluate the efficacy profile of C21 
versus placebo as add on to SoC in 
subjects with COVID -19. • Proportion  of subjects  discharged  
from  hospi[INVESTIGATOR_256928] 8, 22 and 29. 
• Proportion  of hospi[INVESTIGATOR_256929]-invasive,  invasive  mechanical  
ventilation , ECMO  or supplemental  
oxygen  use at Days 8, 15, 22, 29 and 
60. 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 17 of 77 Vicore Pharma AB  • Proportion of subjects in each 
category  of the 8 -point ordinal scale  at 
Days 8, 15, 22,  29 and 60.  
• Duration of hospi[INVESTIGATOR_059] , including 
re-hospi[INVESTIGATOR_059], up to Day 60.  
• Proportion of subjects nee ding 
intensive care unit stay at Day s 8, 15 , 
22, 29 and 60.  
• Duration of intensive care unit stay, 
including re -admission, up to Day 60.  
• Proportion of subjects on  invasive 
mechanical ventilation or ECMO at 
Days 8, 15, 22,  29 and 60,  and 
duration of  use up to Day 60 .  
• Proportion of subjects free of 
respi[INVESTIGATOR_256946] 8, 22, 29 
and 60, and respi[INVESTIGATOR_256931] 60.  
• All-cause mortality up to Days 8, 15, 
22 and 29.  
• Change from baseline in SpO 2/FiO 2 at 
Day 15.  
Exploratory   
• To explore the effect of C21 versus 
placebo as add on to SoC on 
inflammation.  • Change from baseline in CRP at Day 
15. 
• To explore the effect of C21 versus 
placebo as add on to SoC on lung 
injury . • Change from baseline in lactate 
dehydrogenase (LDH) at Day 15 . 
Primary estimand  
All-cause mortality up to Day 60 defined as the time to day of death from any cause assessed for 
the intention -to-treat population with treatment as randomized, independent of treatment 
withdrawal or major protocol deviations according to the treatment policy, with subjects with no 
confir med death before or at Day 60 being censored at day of withdrawal/Day [ADDRESS_312277] ratio with 95% confidence intervals . 
. 
 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 18 of 77 Vicore Pharma AB  Key Seco ndary estimand s 
Time to sustained hospi[INVESTIGATOR_256932] 60 ; The first occurrence of a score ≤ 2 whereafter 
the score stays ≤2 for the remainder of the 60 days trial period, assessed for the intention -to-treat 
population with treatment as randomized,  independent of treatment withdrawal or major protocol 
deviations according to the treatment policy, with subjects who die prior to Day 60 being 
censored at Day 60 and subjects withdrawing due to other causes than death and not fulfilling the 
event being c ensored at the withdrawal day. The Kaplan -Meier difference  in median time to 
sustained hospi[INVESTIGATOR_256947] 95% confidence intervals will be estimated.  
Supplemental o xygen free days up to Day 29;  For each  subject  the number of days between Day 
1 and Day 29 with a score of ≤4 on the 8-point ordinal scale and with no documented use of 
COVID -19 related supplemental oxygen , assessed for the intention -to-treat population with 
treatment as randomized, independent of treatment withdrawal or  major protocol deviations 
according to the treatment policy, with subjects who die prior to Day 29 being  given the value –1 
day and trial withdrawals prior to Day 29 due to other causes than death and not possible to 
follow -up being imputed using multiple imputation including assessments from day 1 to day 29 . 
The Hodge-Lehmann median estimated of  the difference in days between treatments with 95% 
confidence intervals will be estimated.  
Proportion of subjects  free of respi[INVESTIGATOR_256948] 15;  The proportion of subjects with a 
score of ≤[ADDRESS_312278] known status . The difference in proportions between treatments wit h 95% 
confidence intervals will be estimated.  
Proportion  of subjects  discharged  from  hospi[INVESTIGATOR_256949] 15; The 
proportion of subjects with a score of ≤[ADDRESS_312279] known status. The difference in proportions between treatments  with 95% confidence 
intervals will be estimated.  
. 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 19 of 77 Vicore Pharma AB  4. Trial  Design  
4.1. Overall  Design  
This is a  randomized,  double -blind, placebo -controlled, parallel -group, 2 -arm, multicenter trial. 
• Subject s hospi[INVESTIGATOR_256950] -19 will be enrolled . 
• The trial consists of 3 consecutive periods:  a screening period of up to 48 hours , a 2-week  
IMP treatment period and a  follow -up period of up to 7  week s. Daily visits are required 
until discharge. Discharged subjects should return to the clinic for the Day 15  visit.  Days 
8, 22, 29 and 60 visits will be conducted  as phone or video visits for all discharged 
subjects . 
• The trial duration for an individual  subject  will not exceed  9 weeks.  
• The trial will enrol l a total of  maximum 300  randomized subjects , 150 per arm  (C21 100 
mg b.i.d.  or placebo  for 14  days) according to a 1:1 randomization.  
• Blinding will be performed with a matching placebo . 
• Randomi zation  occurs at visit 2 and  will be stratified by:  
o Disease severity  (based on the ordinal scale sco re at Day 1 ). 
o Region.  
• An independent  DMC will actively monitor data from the trial.  
4.2. Scientific Rationale for Trial  Design  
The proposed clinical trial design is based on  the guidance provided in the WHO COVID -19 
therapeutic trial synopsis (WHO, 2020b ), the FDA Guidance for Industry to support clinical 
development of drugs for the treatment and prevention of COVID -19 (FDA, 2 020a ), investig ator 
and authority guidance . 
The trial will enroll hospi[INVESTIGATOR_256951] a confirmed SARS -CoV -2 infection  and on 
supplemental oxygen  but not requiring mechanical invasive ventilation . There is a high unmet 
need for an efficacious  treatment of COVID -19 in this population  to halt respi[INVESTIGATOR_256952].  
The primary endpoint  is all-cause mortality up to Day 60 . This endpoint is considered clinically 
relevant in  the population studied  and the timepoint  of evaluation  will ensure  capturing  the 
majority of events  to assess a treatment response .  
The primary endpoint is supported by [CONTACT_256984] 2 trial  (VP-C21-006), in 
which C21 was associated with a numerical reduction in the mortality rate (one and three deaths 
in the C21 and placebo group, respectively).  All deaths occurred in patients with progressive 
respi[INVESTIGATOR_256953]. One more patient in the placebo 
group deteriorated and developed need for mechanical ventilation.   
The [ADDRESS_312280] been used in the majority of phase 2 and 3 COVID -19 trials to date (Dodd et al., 
2020 ). The 8 -point ordinal scale is a composite measure of clinical improvement and/or survival 
assessed up to [ADDRESS_312281] randomization.  
It has been d emonstrated that there is a strong association between days on oxygen during the 
acute phase of COVID -19 and long -term recovery (Shah et al., 2021 ). In the Phase 2 trial , 
patients on C21 had a significantly lower use of supplementary oxygen therapy at end of 
treatment, only 1 out of 51 subjects in the C21 group was using supplemental oxygen at Day 14 .  
The WHO COVID -19 therapeutic trial synopsis recommends  that s ubjects will be treated with 
IMP on top of SoC in (WHO, 2020b ). Guidance on SoC is provided in Appendix 4  (see Section 
10.4). 
The placebo group and the blinding in the trial  was implemented to minimize bias . The 
randomization will be stratified to ensure an equal distribution  of active and placebo subjects by 
[CONTACT_244945] n and disease severity.  
4.3. Justification for Dose  
Subject s will be treat ed with oral 100 mg C21 or placebo b.i.d. for 14  days.  
The results of the  completed phase 2 trial in COVID -19 subjects (VP -C21-006) and of the phase 
1 trial in healthy subjects ( VP-C21-003) indicate an acceptable safety and tolerability profile for 
the 100 mg b.i.d. dose. The risks of C21 in adults are considered primarily related to reversible 
alopec ia seen at the higher dose of 200 mg b.i.d. In the phase 2 trial in COVID -19 subjects  (VP-
C21-006) and the phase 1 trial (VP-C21-003), the 100 mg b.i.d. dose did not cause any hair loss  
(Further details can be found in the IB ).  Alopecia is therefore not c onsidered to present any 
significant safety risk to subjects in this trial. 
In the phase 1 trial (VP-C21-003), [ADDRESS_312282] and second dose. Lower doses than 100 mg b.i.d. may not 
provide maximal efficacy benefit.  
In the completed phase 2 trial  (VP-C21-006) in COVID -[ADDRESS_312283] s, treatment with 100 mg b.i.d. 
for 7 days , reduced the need for extended oxygen supplementation.  
The recently completed phase 2 trial  (VP-C21-006) indicate s that C21 can prevent hypoxic 
critical illness and based on the course of the disease, there is a strong rational to extend the 
treatment durati on from 7 to 14 days. Furthermore, 27% of subjects within the C21 arm were still 
in need of oxygen (vs 45% on placebo) at the end of the [ADDRESS_312284] completed the trial if he/she has completed all p eriods  of the trial 
including the Day [ADDRESS_312285] s are eligible to be included in the trial only if the following criteria are fulfilled : 
Age 
1. Age ≥[ADDRESS_312286] at the time of signing the informed consent.  (Specific for India ; Age ≥18 at the time 
of signing the informed consent  to ≤65 years .) 
Type of Subject  and Disease Characteristics  
2. Hospi[INVESTIGATOR_256954] -CoV -2 infection confirmed by a hospi[INVESTIGATOR_307] -approved polymerase 
chain reaction (PCR) test, documented by [CONTACT_147664]:  
a. PCR positive in sample collected <72 hours prior to randomization (Visit 2); OR  
b. PCR positive in sample collected ≥72 hours a nd ≤7 days prior to randomization, 
documented inability to obtain a repeat sample AND progressive disease 
suggestive of ongoing SARS -CoV -2 infection.  
3. A score of 5 or 6 on the 8-point ordinal scale : 
a. Score 5: Ho spi[INVESTIGATOR_057], requiring supplemental oxygen . 
b. Score 6: Hospi[INVESTIGATOR_057], on non -invasive ventilation or high -flow oxygen device.  
Sex and Contraceptive/Barrier Requirements  
4. Contraceptive use by [CONTACT_256985] 3 (see Section 10.3). 
Informed Consent  
5. Written informed consent, consistent with International Council for Harmonization  (ICH 
Good Clinical Practi ce (GCP ) R2 and local laws, obtained before the initiation of any trial-
related procedure.  
6. Capable of giving signed informed consent as described in Appendix 1 (see Section 10.1.3 ) 
which includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol . 
Country specific   
7. Specific for India : For subjects with an ordinal scale score of 5 , moderate  to severe 
COVID -19 disease confirmed by  [CONTACT_256986] 2 ≤ 93 % or a respi[INVESTIGATOR_697] ≥ 24/min on room 
air. Note: If a subject  is on supplemental oxygen with SpO2 >93% and respi[INVESTIGATOR_697] 
<24/min , but desaturation to ≤ 93 % or increase of respi[INVESTIGATOR_80753] ≥ 24/min on lower 
supplemental oxygen or room air is documented during screening, the inclusion criterion is 
considered to be met.  
CONFIDENTIAL  VP-C21-[ADDRESS_312287] s are excluded from the trial if any of the following criteria  apply:  
Medical Conditions  
1. Concurrent serious medical condition which in the opi[INVESTIGATOR_256955] s a 
risk or a contraindication for the participation in the trial or that could interfere with the 
trial objectives, conduct or evaluation . 
2. Known , active tuberculosis, active hepatitis B , C, or human immunodeficiency virus  (HIV) 
infection  (i.e., HIV with a CD4 count <500 cells/mm³) . 
3. Moderate or severe impairment of hepatic function  (e.g., Child -Pugh class B or C where 
alterations in the score components are not due to another underlying disease  (see Section 
8.4.5 )). 
4. Severe renal impairment (i.e., estimated glomerular filtration rate (eGFR ) ≤30 
ml/min/1.73 m2). 
5. COVID -19 symptom onset > 21 days prior to screening (Visit 1).  
6. Hospi[INVESTIGATOR_119882] -19 for >72 hours at screening (Visit 1) . 
7. Invasive mechanical ventilation o r ECMO  within 72 hours of screening (Visit 1) . 
8. Expected need  for invasive mechanical ventilation  or ECMO in <48 hours in the opi[INVESTIGATOR_8574].  
9. Moderate to severe ARDS  (e.g., same -day PaO 2/FiO 2 ≤200  mmHg ; or SpO 2/FiO 2 ≤[ADDRESS_312288] is not available ), if on non -invasive mechanical ventilation or high -
flow oxygen . 
10. Pregnant or breast -feeding  female subjects .  
Prior/Concomitant Therapy  
11. Any previous  and concurrent experimental treatment for COVID -19 that is not considered 
local SoC. 
12. Treatment with the medications listed below within 1 week prior to screening (Visit 1)  or 
anticipated need for such medication  during the participation in this trial : 
a. Strong Cytochrome P450 (CYP) 3A4 inducers . 
b. P-glycoprotein ( P-gp) substrates with narrow therapeutic index .  
c. High dose BCRP  sensitive substrates . 
d. Warfarin . 
e. Sulphasalazine or rosuvastatin . 
Prior/Concurrent Clinical Trial  Experience  
13. Current or previous p articipation in any other clinical trial where the subject has received 
a dose of IMP within [ADDRESS_312289] , prior to 
screening (Visit 1) . 
Diagnostic Assessments  
14. Positive pregnancy test (see Section  0). 
15. Abnormal laboratory value at screening (Visit 1)  indicating a potential risk for the subject 
if enrolled in the trial as evaluated by [CONTACT_093] . 
 
 
CONFIDENTIAL  VP-C21-[ADDRESS_312290] s should adhere to meals and dietary restrictions 
regarding food intake:  
• No food intake for 2 hours prior to taking the IMP. 
• No food intake for [ADDRESS_312291] s to meet the Consolidated Standards of 
Reporting Trial s publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, screen failure details,  eligibility criteria, and any 
SAE . Individuals who do not meet the criteria for participation in this trial (screen failure) m ust 
not be re screened . 
CONFIDENTIAL  VP-C21-[ADDRESS_312292]  and Concomitant Therapy  
The IMP is the active  (C21)  or placebo  treatment  intended to be administered to a trial subject  
according to the trial protocol.  
6.1. Investigational Medicinal Product  Administered  
Each  subject will be randomized to  receive treatment with the IMP ( C21 or placebo ). The IMP 
will be administered as a capsule  for oral administration . Each subject will receive 4 capsules per 
day, divided in 2 doses given twice a day . 
IMP will be administered in fasting conditions (see Section  5.3). C21 is  an AT2R agonist . The 
drug substance is 3-[4-(1H-imidazol -1-ylmethyl)phenyl] -5-(2-methylpropyl)thiophene -2-[(N-
butyloxylcarbamate) -sulphonamide] sodium salt supplied as a free form equivalent (eq.) [ADDRESS_312293]  Administe red 
IMP Name  [CONTACT_257005] / C21 Placebo  
Dose Formulation  Capsule  Capsule  
Unit Dose Strength(s)  52.[ADDRESS_312294] bo 
Dosage Level(s)  2 capsules, b.i.d.  2 capsules, b.i.d.  
Excipi[INVESTIGATOR_82013], Anhydrous colloidal 
silica, Magnesium stearate  Mannitol, Anhydrous colloidal 
silica, Magnesium stearate  
Capsule  Vcaps® plus  Vcaps® plus  
Route of 
Administration  Oral Oral 
Dosage description  Subject s will receive [ADDRESS_312295] s will receive Placebo b.i.d. 
on Day 1 to Day 1 4. 
Sourcing  Provided centrally by [CONTACT_256987] a 
container. Each container  will be 
labeled as required per country 
requirement.  IMP will be provided in a 
container. Each container will be 
labeled as required per country 
requirement.  
6.2. Preparation , Handling , Storage , and Accountability  
• The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all IMP received , and any discrepancies are reported and 
resolved before use of the IMP. 
• Only subject s enrolled in the trial may receive IMP, and only authorized site staff may 
supply or administer IMP during hospi[INVESTIGATOR_059] . Prior to dispensing, a ll IMP must be 
stored  at 15 to 25 ° C (59 -77°F)  in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 26 of 77 Vicore Pharma AB  • If a subject is discharged from the hospi[INVESTIGATOR_256956] y 15, IMP accountability will be  
performed,  and the subject will be instructed to self-administer the remaining IMP at 
home . The subject must be instructed to store IMP at room temperature  (15-25°C, 59 -
77°F) . The IMP should be kept in the plastic container  until intake , out of reach from 
children . 
• In subjects  where oral intake becomes a significant challenge  e.g., during  invasive 
mechanical ventilation or ECMO  treatment , IMP will be administ ered as a dispersion , 
either orally or via a nasogastric  or nas oenter al feeding tube. It may also include 
situations in which nasogastric or nasoenteral tube feeding may become required, such as 
non-invasive mechanical ventilation, high flow oxygen therapy and gastric/oesophag al 
discomfort . Route of administrat ion will be collected in the eCRF.  
• The subject should return all used and unused IMP at Visit 16  (Day 15) or at the EWD 
visit for subject withdrawing prior to Visit 16.  
• The investigator  and the pharmacy (if applicable)  are responsible for IMP accountabili ty, 
reconciliation, and record maintenance ( i.e., receipt, reconciliation, and final disposition 
records).  
Further guidance and information  on preparation, handling, storage , and accountability  are 
provided in the IMP handling manual.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
This is a double -blind trial in which subject s, care providers , investigators , outcomes assessors , 
sponsor  and CRO/ vendor  staff are blinded to IMP allocation  i.e., intervention assignment . The 
interactive web respo nse system w ill be programmed with blind -breaking instructions.  
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a subject s’ intervention  assignment is warranted. Subject  safety must always be the firs t 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the investigator should make every effort to contact [CONTACT_1152] a 
subjec t’s intervention  assignment unless this could delay emerg ency treatment for the subject . If 
a subject ’s intervention  assignment is unblinded, the sponsor must be notified within [ADDRESS_312296] ’s intervention assignment, may be sent to investigators in accordance with 
local regulations and/or sponsor policy.  A blinding plan will describ e any unblinded sponsor, or 
CRO /vendor  staff during the conduct of the trial.   
6.4. Investigational Medicinal  Product  Compliance  
When subject s are randomized at the site, they will receive the IMP doses directly from the 
investigator or designee, under medical supervision. The date and time of each dose administered 
in the clinic will be recorded in the source do cuments. The IMP container number  and trial 
CONFIDENTIAL  VP-C21-[ADDRESS_312297]  identification will be confirmed at the time of dosing by a member of the trial site staff 
other than the person dispensing the IMP. 
During the hospi[INVESTIGATOR_059], t he investigator or designee should investigate  and document  if the 
fasting criteria  for the IMP  (see Section  5.3) has been fulfilled.  
If a subject  is discharged from the hospi[INVESTIGATOR_41337] 15  and self-administer the remaining 
IMP at home, IMP compliance and compliance with fasting criteria will be assessed at Visit 16 
(Day 15)  and documented in the source documents and  the eCRF  relevant form . Deviation(s) 
from the prescribed dosage regimen and fasting criteria should be recorded.  
A record of the quantity  of IMP dispensed to and administered by [CONTACT_256988]. Intervention start a nd stop dates, 
including dates for intervention delays and/or dose reductions will also be recorded.  
6.5. Dose Modification  
Dose modifications during the [ADDRESS_312298]  after End 
of Trial  
There will not be continued access  to the  IMP after end of t reatment  (Day 15).  
6.7. Treatment of Overdose  
In this trial, any dose of C21 exceeding a total daily dose of 200 mg  (i.e., 4 capsules of IMP)  is 
considered an overdose.  
Sponsor does not recommend any specific  treatment for an overdose . 
In the event of an overdose, the investigator should : 
• Evaluate the subject  to determine, in consultation with the medical monitor, whether IMP 
treatment  should be interrupted . 
• Closely monitor the subject  for any AE/SAE and laboratory abnormalities . 
• Document the quantity of the excess dose as well as the duration of the overdose.  
Overdoses should be reported as an AE.  
6.8. Prior and Concomitant Therapy  
Concomitant therapy  is defined as a ny medication or vaccine (including over -the-counter , 
prescription medicines, recreational drugs, vitamins, and/or herbal supplements) or other specific 
categories of interest that the subject  is receiving at the time of enrollment or receives during the 
trial. 
SoC for COVID -19 as described in Appendix 4 should be applied during the trial . 
All concomitant therapy and  prior therapy taken up to 4 weeks prior screening (Visit 1)  should 
be recorded.  The investigator must obtain information on m edications and therapi[INVESTIGATOR_256957] e 
COVID -[ADDRESS_312299] be recorded along with:  
• Reason for use . 
• Dates of administration including start and end dates . 
• Dosage information including dose and frequency . 
The medical monitor should be contact[CONTACT_63193].  
COVID -19 vaccination is allowed prior to screening  (Visit 1)  and after the end of the IMP 
treatment period (Day 15) . Vaccination for COVID -19 during the IMP treatment period is 
prohibited . COVID -19 vaccinations  should be recorded in the eCRF.  Treatment with the 
following prohibited medication is not allowed from 1 week prior to screening (Visit 1) and until 
Day 15 (Visit 16):  
a. Strong Cytochrome P450 (CYP) 3A4 inducers  
b. P-glycoprotein (P -gp) substrates with narrow therapeutic index  
c. High dose BCRP sensitive substrates  
d. Warfarin  
e. Sulphasalazine or rosuvastatin  
Strong Cytochrome P450 (CYP) 3A4 inducers, P -glycoprotein (P -gp) substrates with narrow 
therapeutic index and high dose BCRP sensitive substrates  considered prohibited medication  
includ e drugs listed in the FDA tables of substrates, inhibitors and inducers  for drug 
development and drug interactions  (FDA, 2020b ). 
 
 
 
CONFIDENTIAL  VP-C21-[ADDRESS_312300]  
Discontinuation/Withdrawal  
Discontinuation of specific sites or of the trial are detailed in Appendix 1  (see Section 10.1). 
7.1. Discontinuation of Investigational Medicinal Product  
A subject  should be withdrawn from the IMP treatment if  it in the opi[INVESTIGATOR_256958] . 
If IMP treatment  is discontinued , the date of last IMP administration and the date and reason for 
treatment withdrawal should be reported  in the eCRF. If a subject  is removed from treatment 
because of an AE, the reason for treatment withdrawal should always be stated as ‘adverse event’ 
irrespective of whether this was the investigator’s or the subject ’s decision.  
If IMP treatment is discontinued, the investigator sh ould make all efforts to ensure that the 
subject  will remain in the trial and ensure that the subject attend s the remaining visits  in the trial . 
IMP treatment should be discontinued in case of drug induced liver injury  according to criteria 
specified in  FDA guidance (FDA, 2009 ), moderate or severe impairment  of hepatic function 
(e.g., Child -Pugh c lass B or C where alterations in the score components are not due to another 
underlying disease (see Section 8.4.5 )), or s evere renal impairment (i.e., estimated glomerular 
filtration rate (eGFR) ≤30 ml/min/1.73 m2).  
7.1.1.  Temporary Discontinuation  
There are no specifi c criteria for t emporary discontinu ation of IMP treatment . If temporary 
discontinuation of IMP is required  according to investi gator’s judgement , the date and reason for 
a temporary  discontinuation should be reported  in the eCRF.  If the subject is still within the 
treatment period of the trial when a temporary discontinuation is no longer required, IMP 
treatment can be restarted.  
7.2. Subject  Discontinuation/ Withdrawal from the Trial  
• A subject  may withdraw from the trial at any time at his/her own request  i.e., withdrawal 
of consent .  
• At the time of discontinuing from the trial, if possible, an EWD  visit should be 
conducted,  as described  in the S oA. 
• The subject  will be permanently discontinued from the IMP at the time  of withdrawal  
from the trial . 
• If the subject  withdraws consent  for disclos ure of future information, the s ponsor may 
retain and continue to use any data collected before such a withdrawal of consent . 
• If a subject  withdraws from the trial, he/she may request destruction of any samples taken 
and not tested , and the investigator must document this in the site trial records . 
 
 
CONFIDENTIAL  VP-C21-[ADDRESS_312301] to follow -up if he /she repeatedly fails to return for scheduled 
visits an d is unable to be contact[CONTACT_54089]. 
The following actions must be taken if a subject  fails to return to the clinic for a required trial 
visit:  
• The site must attempt to contact [CONTACT_18997], counsel the subject  on the importance of maintaining the assigned visit schedule 
and ascertain whether the subject  wishes to and/or should continue in the trial. 
• Before a subject  is deemed lost to follo w-up, the investigator or designee must make 
every effort to regain contact [CONTACT_1155]  (where possible, [ADDRESS_312302] ’s last known mailing address or local equivalent 
methods). These contact [CONTACT_256989] ’s medical record.  
• Should the subject  continue to be unreachable, he/she will be considered to have 
withdrawn from the trial. 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 31 of 77 Vicore Pharma AB  8. Trial  Assessments and Procedures  
• Trial  procedures and their timing are summarized in the  SoA.  Protocol waiver s or 
exemptions are not allowed.  
• Immediate  safety concerns  should be discussed with the s ponsor  or designee  immediately 
upon occurrence or awareness to determine if the subject  should continue or discontinue 
IMP. 
• Adherence to the trial design requirements, including those specified in the SoA, is 
essential and required for trial conduct.  
• All screening evaluations must be completed and reviewed to confirm that  potential 
subject s meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all subject s screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
• Procedures conducted as part of the subject ’s routine clinical management (e .g., PCR 
tests for SARS -CoV -2 collected less than 3 days prior to Visit 2 (or less than [ADDRESS_312303] ive of ongoing SARS -CoV -2 infection )) and obtained before signing of 
the ICF may be utilized for screening or baseline purposes provided the procedures met 
the protocol -specified criteria and were performed within the timeframe defined in the 
SoA. 
The maximum amount of blood collected from each subject  over the duration of the trial, 
including any extra assessments that may be required, will not exceed 130 mL. 
8.1. Screening Assessments  
Planned timepoints for all screening  assessments are provided in the SoA.  Screening procedures 
may be done over 1 to 2  calendar days .  
8.1.1.  Demographics  
Demog raphic and baseline characteristics will be obtained. This following information will be 
collected:  
• Age at screening  
• Race and ethnicity  
• Sex 
• Height  
• Body weight  
 
8.1.2.  Medical History  
All c urrent medical conditions  and relevant previous medical conditions according to 
investigator judgement should be recorded . 
The medical history should include the following information:  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 32 of 77 Vicore Pharma AB  • Date of onset of COVID -19 signs and symptoms.  
• Date of COVID -19 diagnosis  (defined as sample date for positive COVID -19 PCR tes t). 
• History of chronic medical conditions including chronic supplemental oxygen 
requirement prior to onset of COVID -19 signs and symptoms . 
• History of previous COVID -19 diagnosis and serology results (if  relevant and known).  
8.2. Efficacy Assessments  
Planned timepoints for all efficacy assessments are provided in the SoA.  
8.2.1.  8-point Ordinal Scale  
The clinical status  of COVID -19 is scored at each visit according to the 8-point ordinal scale  
(Beigel et al., 202 0), which is an investigator evaluation  of the clinical status at the first 
assessment of a given trial day. The clinical status of COVID -[ADDRESS_312304] further be scored  at the time of hospi[INVESTIGATOR_2345] . For subjects hospi[INVESTIGATOR_256959] 29 (Visit 31) and Day 60 (Visit 32) , the clinical status of COVID -19 should be scored  each 
time a change in clinical COVID -19 status is seen  and until hospi[INVESTIGATOR_2345] .  
The 8-point ordinal scale is as follows:  
1. Not ho spi[INVESTIGATOR_057], no limitations on activities  
2. Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen  
3. Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires 
ongoing medical care  
4. Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - requiring ongoing 
medical care (COVID -19-related or otherwise)  
5. Hospi[INVESTIGATOR_057], requiring supplemental oxygen  
6. Hospi[INVESTIGATOR_057], on non -invasive ventilation or high flow oxygen devices  
7. Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO  
8. Death  
A subject re-admi tted to the hospi[INVESTIGATOR_34092] a non -COVID -19 related reason  should be considered 
not hospi[INVESTIGATOR_256960] -19 on the 8 -point ordinal scale.   
8.2.2.  Supplemental Oxygen  
Any daily need f or supplemental oxygen  will be recorded at each visit from screening (Visit 1) to 
Day 29.  This will include use of supplemental oxygen  during hospi[INVESTIGATOR_256961] .  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 33 of 77 Vicore Pharma AB  8.2.3.  Oxygen Saturation  
• Resting p eripheral capi[INVESTIGATOR_19365] (SpO 2) will be performed as outlined in 
the S oA. 
• SpO [ADDRESS_312305]  in a quiet 
setting . 
• SpO 2 will be recorded  up to  2 times  with a 5 -minute interval  between the measurements .  
• Supplemental oxygen flow  rate (L/min) , oxygen delivery device , FiO 2, airway pressure, 
if applicable,  must be assessed at the time of measuring SpO 2. 
8.3. Survival and Hospi[INVESTIGATOR_256962] , hospi[INVESTIGATOR_256963]-admission s will be collected at each visit 
from Day 2 (Visit 3) to Day 60 (end-of-trial). Information on the hospi[INVESTIGATOR_6885] , including 
intensive care unit ( ICU), high flow oxygen device  use, ventilat or use (Non -invasive, Invasive or 
ECMO)  will be collected.  
8.4. Safety Assessments  
Planned  timepoints for all safety assessments are provided in the SoA (see Section  1.3). 
8.4.1.  Physical Examinations  
• Physical examination s will be performed as outlined in the SoA (see Section  1.3). 
• The physical examination will include assessments of the  respi[INVESTIGATOR_256964]. Other systems will be assessed per investigator judgment.   
• Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
• Each body system will be reported as “normal” or “abnormal”. Any clinical ly significant 
abnormalities prior to initiation of IMP should be specified and recorded as medical 
history.  New clinically significant abnormalities  occurring after initiation of IMP should 
be reported as AE s. 
8.4.2.  Vital Signs  
• Body temperature, pulse rate, respi[INVESTIGATOR_256965]  (see Section  1.3). 
• Blood pressure , respi[INVESTIGATOR_256966] [ADDRESS_312306]  in a quiet setting without distractions ( e.g., television, cell 
phones).  
• Vital signs (to be taken before blood collection for laboratory tests) will consist of 1 pulse 
and 3 blood pressure measurements ([ADDRESS_312307] 1 minute).  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 34 of 77 Vicore Pharma AB  • Any clinically significant abnormalities prior to initiation of IMP should be specified and 
recorded as medical history.  New clinically significant abnormalities  occurring after 
initiation of IMP should be reported as AE s. 
8.4.3.  Electrocardiograms  
• 12-lead electrocardiograms ( ECGs ) will be obtained as outlined in the SoA (see 
Section  1.3) using local  ECG equipment that automatically calculates the heart rate and 
measures PR, QRS, QT, and QTcF intervals.  
• Historical 12 -lead ECG s are acceptable  if ≤2 days old at the time of screening ( Visit 1 ). 
• The ECG assessment will be reported as “normal” or “abnormal”. Any clinical ly 
significant abnormalities should be specified and recorded as medical history.  
8.4.4.  Clinical Safety Laboratory Tests  
• Blood and urine samples for clinical safety laboratory tests will be collected as outlined 
in the SoA (see Section  1.3). Samples collected at screening ( Visit 1 ) will be analyzed 
using local laboratories  and used to  confirm eligibility  for participation in the trial .  
• Day 1 (Visit 2), samples will be collected before IMP administration.  
• Samples collected at all other visits will  be analyzed by [CONTACT_2237].  
• If needed due to special c ircumstances e.g ., delays in turn -around time due to COVID -19, 
blood samples may be analyzed locally after sponsor approval . 
• The tests detailed in Table 2 will be performed . 
  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 35 of 77 Vicore Pharma AB  Table 2. Protocol -required Safety Laboratory Tests  
Laboratory 
Tests Parameters  
Hematology  Platelet count (thrombocytic 
particle concentration)  
Hemoglobin  
Hematocrit  (erythrocyte volume 
fraction)  
Mean corpuscular volume ( MCV ) 
 White blood cell (WBC) count with 
differential:  
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  
Clinical 
chemistry  Blood urea nitrogen  (BUN ) 
Glucose , fasting  
Potassium  
Sodium  
Calcium  
Ferritin  
Prothrombin time  (PT) 
International Normalized Ratio  
(INR)  
activated partial thromboplastin 
time (aP TT) AST  
Alanine transferase ( ALT ) 
Alkaline phosphatase  (ALP)  
Albumin  
Total and direct bilirubin  
Serum creatinine  
eGFR  
CRP  
LDH  
Routine 
urinalysis  • pH, glucose, protein, ketones, bilirubin, urobilinogen, and specific  
gravity by  [CONTACT_5230]  
• Microscopic examination ( per investigator judgment ) 
Pregnancy 
testing  • Highly sensitive urine  or serum  human chorionic gonadotropin 
pregnancy test (as needed for women of childbearing potential)  
• Investigators must review of each laboratory safety report.  Any clinically significant 
abnormalities at screening ( Visit 1 ) or Day 1 (Visit 2) will be reported as medical history. 
New clinically significant abnormalities after Day 1 ( Visit 2 ) should be reported as AEs.  
8.4.5.  Hepatic Impairment   
In subjects with h epatic impairment , the grade of impairment will be assessed by [CONTACT_256990] r andomization and as needed during the trial using the Child -Pugh system  (FDA, 2003 ). 
For subjects assessed using the Child -Pugh system , it is important that impaired hepatic function , 
not another  underlying disease , is the cause of alterations in the Child -Pugh components 
(bilirubin, albumin, prothrombin  time, encephalopathy , and ascites). Scoring will be performed 
according to  Table 3 and the classification will be based on the total score;  
• Class A (mild) : 5 or 6 points  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 36 of 77 Vicore Pharma AB  • Class B (moderate) : 7 to 9 points  
• Class C ( severe ): 10 to 15 points   
 
Table 3. Child -Pugh System  
 Points scored for observed findings  
1 2 3 
Encephalopathy grade1) None  1 or 2  3 or 4  
Ascites  Absent  Slight  Moderate  
Total bilirubin2) <2 mg/dL  
 
(<34.2 µmol/L)  2 to 3 mg/dL  
 
(34.2 to 51.3 µmol/L)  >3 mg/dL  
 
(>51.3 µmol/L)  
Serum albumin2) >3.5 g/dL  
 
(>35 g/L)  2.8 to 3.5 g/dL  
 
(28 to 35 g/L)  <2.8 g/d L 
 
(<28 g/L)  
Prothrombin time, sec 
prolonged (or INR as 
below)  
 
INR <4 
 
 
 
<1.7 4 to 6  
 
 
 
1.7 to 2.3  >6 
 
 
 
>2.3 
1) Grade 0: normal consciousness, personality, neurological examination, electroencephalogram  
Grade 1: restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cps waves  
Grade 2: lethargic, time -disoriented, inappropriate, asterixis, ataxia, slow triphasic waves  
Grade 3: somnolent, stuporous, place -disoriented, hyperactive r eflexes, rigidity, slower waves  
Grade 4: unrousable coma, no personality/behavior, decerebrate, slow 2 -3 cps delta activity  
2) If using results from the central laboratory for calculating the scores, the alternative units may have to be 
considered  
8.4.6.  Pregnancy Testing  
Women of childbearing potential will undergo pregnancy tests (urine dip -sticks  or serum if 
required by [CONTACT_427] ) at the screening and Day [ADDRESS_312308] will be reported as “positive” or “negative”  in 
the eCRF . If the urine pregnancy test is positive, a blood pregnancy test will be performed to 
confirm positive pregnancy.   
Women of non -childbearing potential are defined as pre -menopausal females who are st erilised 
(tubal ligation or permanent bilateral occlusion of fallopi[INVESTIGATOR_2134]); or post -menopausal defined as 
12 months of amenorrhea)  (see Section 10.3). 
Additional serum or urine pregnancy tests may be performed, as determined necessary by [CONTACT_41011], to establish the absence of pregnancy at any time 
during the subject ’s participation in the trial. 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 37 of 77 Vicore Pharma AB  8.4.7.  SARS -CoV -2 Variant  
Oropharyngeal swabs will be collected as outlined in the SoA (see Section  1.3). A central 
laboratory  will determine the SARS -CoV -2 variant.    
8.4.8.  New Infections  
Information on new infections  (viral and non -viral)  should be reported as AEs.  Information should 
preferably include  the site of infection and source of culture . 
8.5. Adverse Events , Serious Adverse Events, and Other Safety 
Reporting  
The definitions of AEs and SAEs can be found in Appendix  2 (see Section  10.2). 
AEs will be reported by [CONTACT_423]  (or, when appropriate, by a caregiver, surrogate, or the 
subject ’s legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE a nd remain responsible for following 
up all AEs  OR AEs that are serious, considered related to the IMP or trial procedures, or that 
caused the subject  to discontinue the IMP or trial (see Section 7). 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 2 (see Section 
10.2). 
8.5.1.  Time Period and Frequency for Collecting AE and SAE Information  
All AEs will be collected from signing of the ICF until Day 29 at the timepoints specified in the 
SoA (see Section  1.3). SAEs will  further be collected until Day [ADDRESS_312309] reached a final outcome  (see Section 10.2) or the subject’s participation in the trial 
ends, whichever comes first .  
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours  after SAE awareness , as indicated in Appendix 2 (see 
Section 10.2). The investigator will submit any updated SAE data to the sponsor within [ADDRESS_312310]  has been discharged from the trial, and he/she considers the event to be 
reasonably related to the IMP or trial participation, the investigato r must promptly notify the 
sponsor  regardless of the time that has elapsed (post -trial events) . 
8.5.2.  Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the subject  is the preferred method to inquire about AE 
occurrences.  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 38 of 77 Vicore Pharma AB  8.5.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the inv estigator is required to proactively follow each subject  at 
subsequent visits/contacts. All SAEs  will be followed until resolution, stabilization, the event is 
otherwise explained, or the subject  is lost to follow -up (see Section 7.3). Further information on 
follow -up procedures is provided in Appendix 2 (see Section 10.2). 
8.5.4.  Regulatory Reporting Requirements for SAEs  
• Prompt notification – within [ADDRESS_312311] s and the safety of the IMP under clinical investigation are 
met. 
• The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of the IMP under clinical investigation. The 
sponsor will comply with country -specific regulatory requirements relating to safety 
reporting to the regulatory authority, institutional review board ( IRB)s/ independent 
ethics committee  (IEC)s, and investigators.  
• An inv estigator who receives an investigator safety report describing an SAE or other 
specific safety information ( e.g., summary or listing of SAEs) from the sponsor will 
review and then file it in the investigator site file  and will notify the IRB/IEC, if 
appro priate according to local requirements.  
8.5.5.  Pregnancy  
• Details of all pregnancies in female subject s and female partners of male subject s will be 
collected after the start of IMP and until the end of trial visit.  
• If a pregnancy is reported, the investigator will record pregnancy information on the 
appropriate form and submit it to  the sponsor within [ADDRESS_312312]  (after obtaining the necessary signed informed 
consent from the female p artner)  pregnancy.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be reported 
as an AE or SAE.  
• Abnormal pregnancy outcomes ( e.g., spontaneous abortion,  fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs  and will be reported as 
such. 
• The subject /pregnant female partner  will be followed to determine the outcome of the 
pregnancy. The investigator will collect follow -up inf ormation on the subject /pregnant 
female partner  and the neonate,  and the information will be forwarded to the sponsor.  
• Any post trial pregnancy -related SAE considered reasonably related to the IMP by [CONTACT_129161] (see Section  8.5.4 ). While the investigator is 
not obligated to actively seek this information  in former trial subject s/pregnant female 
partner , he or she may learn of an SAE through spontaneous reporting.  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 39 of 77 Vicore Pharma AB  8.6. Pharmacokinetics  
• PK data will be collected  at a pre-selected  number of trial sites in a subgroup of 
approximately 10  subjects . 
• Blood  samples of approximately 3 mL will be collected for measurement of plasma  
concentrations of C21 as specified in the SoA ( see Section 1.3). At Day 1 (Visit 2), b lood 
samp les will be collected before the first IMP administration and 30 minutes, 1, 2, 3 , 4 
and 6 hours after the IMP administration . 
• Instructions for the collection and handling of biological samples will be provided by [CONTACT_103]. The actual date and time (24 -hour clock time) of each sample as well as the date 
and time of the IMP administration will be recorded.  
• PK data will not be re ported to the trial sites, sponsor or blinded CRO /vendor  staff until 
the trial has been unblinded . 
• The individual plasma  concentration data, and the actual time for IMP administration and 
blood sampling will be used throughout the analyses.   
• All C21 plasma  concentration data collected in this trial can be included in population PK 
and population PK/PD analyses with the objective of exploring the impact of covariates 
(e.g., body weight and age) on the PK of C21 , or the relationship between the C21 
exposure a nd selected efficacy and safety endpoints. Any p opulation PK and population 
PK/PD analyses will be reported separately.  
• From t he plasma C21 concentration data analysis , the following PK variables will be 
derived  using non -compartmenta l analysis : 
• Cmax - Observed maximum plasma concentration of C21.  
• tmax - Time to reach C max following IMP administration.  
• AUC (0-6) - Area under the plasma concentration curve from time zero to 6 hours.  
• AUC last - Area under the plasma  concentration -time curve from time zero to the last 
quantifiable concentration.  
• AUC (0-inf) - Area under the plasma concentration -time curve from time zero 
extrapolated to infinity.  
• t½ - Apparent terminal half -life. 
• C6 - Actual plasma concentration of C21 at 6 hours after IMP administration . 
8.7. Genetics  
Genetics are not evaluated in this trial. 
8.8. Biomarkers  
• Plasma  samples will be collected to investigate a range of laboratory parameters as 
potential biomarkers of inflammation, fibrosis , and viral activity  including serology . 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 40 of 77 Vicore Pharma AB  Samples will be collected according to the schedule described in the SoA and as detailed 
in laboratory manual provided separately to sites .  
• Sponsor  may store and analyze samples for up to 2 years after the end of th e trial to 
achieve trial objectives.  
• Biomarker  results will be reported separately from the clinical trial report . 
8.9. Immunogenicity Assessments  
Immunogenicity is not evaluated in this trial. 
8.10. Health Economic s OR Medical Resource Utilization and Health 
Economic s 
Medical resource utilization  and health economics parameters  will be evaluated in terms of days 
hospi[INVESTIGATOR_256967] . Additional analyses may be conducted outside of the 
clinical trial report.  
CONFIDENTIAL  VP-C21-[ADDRESS_312313] the alternative hypothesis that C21 is better than placebo. All 
tests will be done using 2 -sided alternatives . 
9.1.1.  Multiplicity Adjustment  
The statistical comparisons for the primary e fficacy endpoint and the key secondary endpoint 
will be carried out in following  hierarchical order ; all-cause mortality up to Day 60 , time to 
sustained hospi[INVESTIGATOR_256932] 60 , supplemental oxygen free days up to Day 29, 
proportion of subjects free of respi[INVESTIGATOR_256948] 15 , and proportion of subjects discharged 
from hospi[INVESTIGATOR_256968] 15 . This means that statistically significant 
results for the comparison in the higher rank are required to initiate the testi ng of the next 
comparison in the lower rank. Since a step -down procedure is used, each comparison will be 
tested at a significance level of 0.05 and an overall alpha level of 0.05 will be preserved .  
9.2. Analysis Sets  
For the purposes of analysis, the followin g analysis sets are defined:  
 
Subject  Analysis Set  Description  
Intention to treat (ITT) 
analysis set  All randomized subjects . Subject s will be included in the analyses 
according to the intervention they were randomized to.  
Per protocol (PP) analysis 
set All subjects  in the ITT set without major protocol deviations deemed 
to have an impact on efficacy readouts. In addition, subjects who 
prematurely discontinued IMP during the treatment period but 
continued with data collection in the trial will also be exclude d from 
the P P. Subjects with drawn  from the trial unrelated to trial 
participation  due to extraordinary circumstances (for example 
subjects lost -to follow up due to unstable geopolitical situation) may 
also be excluded from the PP set (furt her specified in the SAP).  
Subjects  will be included i n the analyses according to the intervention 
they were randomized to.  
Safety analysis set  All randomized subjects  who are exposed to IMP. Subjects  will be 
analyzed according to the actual intervention received.  
CONFIDENTIAL  VP-C21-[ADDRESS_312314] the PK analyses.   
9.3. Statistical Analyses  
9.3.1.  General Considerations  
All tests will be 2 -sided at a 5% significance level.  
Baseline will be defined as t he last non -missing assessment obtained prior to first IMP 
administration.  
Stratification will be done based on baseline disease severity , that is the score on the ordinal 
scale at baseline ( 5 or 6), and region ( North America, South and Central America, Eu rope, 
Africa, or Asia ). The a ctual stratification will be used as factors in the statistical analysis , 
subjects included in wrong stratum at randomization will be moved to their correct strata 
belonging  in the analyses . Due to small strata, the regions may  be merged ; details of this will be 
given in the SAP.  
Continuous variables will be summari zed using (arithmetic) means, standard deviation  (SD) , 
median, minimum , and maximum value, categorical variable s will be summari zed using numbers 
and percentages.  For variables with an expected skew distribution, geometric means , and 
coefficient of variation (CV) will be used instead of arithmetic means an d SD . 
The ITT analysis set is used to analyze endpoints related to the efficacy objectives, the PP 
analysis set will be used for sensitivity analyses related to efficacy objectives and the safety 
analysis set is used to analyze the endpoints and assessments related to safety.  PK data will be 
presented using the PK analysis set.  
All data regarding subject characteristics, efficacy and safety will be listed.  
9.3.2.  Primary Endpoint/Estimand  Analysis  
The primary endpoint, all-cause mortality up to Day 60, will be defined as the time to day of 
death from any cause within Day [ADDRESS_312315] adjusting for 
treatment, baseline disease severity ( score on ordinal scale at baseline) and region. The size of 
the treatment effect will be given as a hazard ratio with 95% confidence intervals . Analysis will 
be illustrated using a Kaplan -Meier plot .  
As a sensitivity analysis , the proportion of subjects w ith death up to Day [ADDRESS_312316] error for the difference and the associated 95% 
confidence interval  (Ge et al., 2011 ). In addition, the raw proportions per treatment grou p will be 
given.  
The ITT analysis set will be used for primary analysis and sensitivity analysis will be performed 
using the PP analysis set , subjects will be included as randomized. All collected data post-
treatment will be used  to assess the s tatus of th e subjects . Impact of subjects not properly being 
followed -up regarding status at Day [ADDRESS_312317] 
occurrence of a score of ≤[ADDRESS_312318] stay ≤2 for the remainder of the trial (no re -hospi[INVESTIGATOR_256969] -19). 
Treatment groups will be compared using a stratified log -rank test adjusting for treatment, 
baseline disease severi ty and region. The size of the treatment effect will be given as a hazard 
ratio with 95% confidence intervals. Analysis will be illustrated using a Kaplan -Meier plot and, 
if a sufficient number meet s the endpoint, the median time to hospi[INVESTIGATOR_256970] 95% confidence intervals for each treatment group. Subjects who die prior to Day [ADDRESS_312319]  with a score of ≤[ADDRESS_312320] and 
the treatment difference will be expressed as the Hodge -Lehmann difference  in median number 
of days with 95% confidence intervals . All collected data post -treatment will be used. Subject s 
who die prior to Day 29 will be given the value of –1 day in the analysis and trial withdrawals 
prior to Day 29 due to other causes of death will be imputed  (for each day) using  multiple 
imputation including status for all of days [ADDRESS_312321]  key secondary endpoint , subjects free of respi[INVESTIGATOR_1399] , will be defined as subjects 
with a n ordinal scale score of ≤[ADDRESS_312322] known status into account . The adjusted proportions as 
calculated from (Ge et al., 2011 ) and the statistics (treatment difference, SE and C I) following 
multiple imputation will also be presented.  The ITT will be used for the analysis. The number of 
responders/non -responders will also be presented (these will be the non -imputed values).   
The fourth  key secondary endpoint, proportion of subjec ts discharged from hospi[INVESTIGATOR_256971] 15 , will be defined as subjects with a score of ≤[ADDRESS_312323] known status into account. The adjusted 
proportions as calculated from (Ge et al., 2011 ) and the statistics  (treatment difference, SE and 
CI) following multiple imputation will also be presented.  The ITT will be used for the analysis. 
The number of responders/non -responders will also be presented (these will be the non -imputed 
values).  
Other e ndpoints assessing  proportion of subjects will be compared using similar logistic 
regression models as for the primary endpoint  with the treatment effect expressed as a difference 
in proportions . Death prior to endpoint readout will be handled as worst case, that is subject  will 
be assumed to be in mechanical ventilator need or to be in oxygen need  or not to have fulfilled 
an improvement of [ADDRESS_312324] is 
hospi[INVESTIGATOR_256972] -19 will be used for computation with imputation of days as being in 
event for subjects in ventilator care an d for subjects  with death as outcome.  For duration of I CU 
stay, subjects  with no ICU stay will be given the value 0 days in the analysis and subjects with 
death as outcome will be considered in ICU from time of death until end of observational period.  
The change from baseline to Day 15  in SpO 2/FiO 2 will be com pared between treatment groups 
using an analysis of covariance (ANCOVA) model with treatment , baseline disease severity  and 
region as factor s and the baseline SpO2/FiO2  as covariate.  The adjusted mean difference 
between treatments will be given together with 95% confidence intervals and associated 2 -sided 
p-value.  
9.3.4.  Exploratory Endpoint  Analysis  
The change in CRP  and LDH  from baseline up to Day 15 will be compared between treatment 
groups with ANCOVA models adjusting for treatment, baseline disease  severity and region as 
factors and baseline as a covariate. Model for CRP  and LDH  will be multiplicative, that is data 
being log-transformed prior to analysis and the result back -transformed to the linear scale.  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 45 of 77 Vicore Pharma AB  9.3.5.  Safety Analyses  
Safety analysis will be bas ed on the safety set.  
AEs will be analyzed using quantitative and qualitative measures. Treatment -emergent AEs 
(TEAEs)  will be summarized by [CONTACT_256991], related AEs,  SAEs,  deaths, AEs 
leading to discontinuation of blinded IMP treatment  or to withdrawal from trial, AEs of different 
severity and AEs of different chronicity. AEs will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA) and summarized by [CONTACT_104579].  
Laboratory data will be summarized by [CONTACT_256992]. The number 
of high, low , and normal  values for each continuous parameter , and the normal and abnormal 
values for each categorical parameter,  will be summarized for change over  time using shift 
tables.  
Vital signs  (body temperature, pulse  rate, respi[INVESTIGATOR_697] , and blood pressure) will be 
summarized by [CONTACT_256992].  Abnormalities find at physical 
examination will be summarized by [CONTACT_765]. Outcome of pregnancy tests will be listed.  
9.3.6.  Other Analyses  
The subject  flow including total number of screened subjects , number of randomized subject s, 
completers, withdrawn subjects  (including reason for withdrawal) and subjects  included in each 
of the analysis sets will be summarized by [CONTACT_256993].  
The number of subjects  with major protocol deviations will be summarized by [CONTACT_256994] s leading to 
exclusion from the per -protocol analysis set. 
Demographic and baseline characteristics will be summarized using descriptive statistics for 
each treatment group and for the total number of randomized subjects . Medical history will be 
coded using MedDRA and summarized by [CONTACT_256995]. Prior medications will denote medications used prior to first dose of IMP 
independent of if stopped at randomization or not. Concomitant therapy  will denote medications 
started prior to but continuing after randomization or medications with a start date at or after the 
randomization date. Prior and concomitant therapy  will be summarized separately by [CONTACT_256996] 2 and 4.  
Several sensitivity analyses will be performed on the primary and key secondary  endpoints 
regarding choice of population (PP population) and choice of imputation  for missing data. 
Specifically tippi[INVESTIGATOR_256973] .  
Subgroup analyses of the primary and key s econdary endpoint s will be made to assess 
consistency of the intervention effect across at least the following subgroups:  
• Age group: <65 vs ≥65 years  
• Sex: female vs male  
• Baseline disease severity ( 8-point o rdinal scale 5 or 6 at Day 1 ) 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 46 of 77 Vicore Pharma AB  • Race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White or Other)  
• Ethnicity (Hispanic or Latino, Not Hispanic or Latino)  
• Region ( North America, South and Central America, Europe, Africa, or Asia ) 
• Presence  of risk factors for severe COVID -19 (Yes, No)  
 
If the number of subjects is too small (less than 10%) within a subgroup, then the subgroup 
categories may be redefined prior to unblinding the trial. Further details on the statistical analysis 
will be prov ided in the SAP.  
9.4. Interim Analys is 
No formal interim analysis will be performed. The DMC will review the safety results after the 
first [ADDRESS_312325] completed trial up to Day 15.  
9.5. Sample Size Determination  
The sample size is based on the all-cause mortality  up to  Day 60. For the placebo  (SOC ) group , 
the proportion of subjects dead at Day 60 is estimated to 10 % (Marconi et al., 2021 ).   
With [ADDRESS_312326] s per trial group, there will be a n 80% power to detect a difference 
between C21 and placebo if the proportion of subjects  dead at Day 60 in the C21 group is  2.5% 
(corresponding to a HR of 0.24) . In this calculation , a 5% withdrawal rate  has been assumed. For 
the actual detection limit (corresponding to 50% power), if [ADDRESS_312327] at a 5% significance level.  Analysis will be by [CONTACT_7586] -to-
treat;  thus,  all randomized subject s should be accounted for in the statistical evaluation.   
 
 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 47 of 77 Vicore Pharma AB  10. Supporting Documentation and Operational Considerat ions 
10.1. Appendix 1: Regulatory, Ethical, and Trial  Oversight Considerations  
10.1.1.  Regulatory and Ethical Considerations  
• This trial will be conducted in accordance with the protocol and with the following:  
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences internationa l ethical guidelines . 
o Applicable ICH GCP guidelines . 
o Applicable laws and regulations . 
• The protocol, protocol amendments, ICF,  IB and other relevant documents ( e.g., 
advertisements) must be submitted to an IRB/IEC by [CONTACT_256997]/IEC before the trial is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes except for changes necessary to eliminate an immediate hazard to trial subject s. 
• Protocols and any substantial am endments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate 
hazard to trial subject s. 
• The investigator will be responsible for the following:  
o Providing written summaries of the status of the trial to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC . 
o Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures . 
o Providing oversight of the conduct of the trial at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies, and all other applicable local regulations . 
10.1.2.  Financial Disclosur e 
Investigators and sub -investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigato rs are 
responsible for providing information on financial interests during the trial and for 1 year after 
completion of the trial. 
10.1.3.  Informed Consent Process  
• The investigator or his/her representative will explain the nature of the trial, including the 
risks  and benefits, to the subject  and answer all questions regarding the trial. 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 48 of 77 Vicore Pharma AB  • Subject s must be informed that their participation is voluntary. Subject s will be required 
to sign a statement of informed consent that meets the requirements of 21 CFR 50  (US 
only), local regulations, ICH guidelines, privacy , and data protection  requirements, where 
applicable, and the IRB/IEC or trial center.  
• The medical record must include a statement that written informed consent was obtained 
before the subject  was enrolled in th e trial and the date the written consent was obtained. 
The authorized person obtaining the informed consent must also sign the ICF.  
• Subject s must be reconsented , as applicable , to the most current version of the ICF(s) 
during their participation in the trial. 
• A copy of the ICF(s) must be provided to the subject .  
10.1.4.  Data Protection  
• Subject s will be assigned a unique identifier by [CONTACT_456]. Any subject  records or 
datasets that are transferred to the sponsor will contain the identifier only; subject  names 
or any information which would make the subject  identi fiable will not be transferred.  
• The subject  must be informed that his/her personal trial-related data will be used by [CONTACT_20004]. The level of disclosure must also b e 
explained to the subject  who will be required to give consent for their data to be used as 
described in the informed consent . 
• The subject  must be informed that his/her medical records may be directly examined by 
[CONTACT_78582], by [CONTACT_6667]/IEC members, and by [CONTACT_6668].  
10.1.5.  Committees St ructure  
[IP_ADDRESS].  Data Monitoring Committee  
An independe nt DMC will be established.  The functions and responsibilities of the DMC will be  
described in a DMC charter.  
Throughout the duration of the trial, the DMC will evaluate all S [LOCATION_003]Rs  on an ongoing basis. 
The DMC is scheduled to meet twice  during trial conduct , to review unblinded safety data from 
the trial after data collection for [ADDRESS_312328]  25% of randomi zed subjects , and to review 
safety and efficacy data after data colle ction for [ADDRESS_312329] 50% of randomized  subjects . 
In addition, the DMC member s may call for an ad hoc  safety review meeting at any time  during 
the trial . This may include a  review of unblinded safety data after data collection for [ADDRESS_312330] 75% of randomized  subjects . The DMC will  provide appropriate written 
recommendations to the sponsor regarding trial continuation, protocol modifications or trial 
suspension.  The DMC will operate unblinded  and independent from all sites, CRO, vendor and 
sponsor staff involved in the conduct of the trial . 
10.1.6.  Dissemination of Clinical Trial  Data  
Information  about the clinical trial and tabular trial results will be posted on the US National 
Institutes of Health’s website www.clinicaltrials.gov  and on the  European Union Drug 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 49 of 77 Vicore Pharma AB  Regulating Authorities Clinical Trials Database ( EudraCT) prior to first subject first visit and 
after trial completions. Information about the  clinical trial may also be posted on other 
governmental webpages according to local regulations.  
10.1.7.  Data Quality Assurance  
• All subject  data relating to the trial will be entered into  electronic CRF s unless 
transmitted to the sponsor or designee electronically (Central laboratory data). The 
investigator is responsible for verifying that data entries are accurate and correct by 
[CONTACT_113559].  
• Guidance on completion of CRFs will be prov ided in CRF completion guideline  provided 
separately to sites . 
• The investigator must permit trial-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
• Quality tolerance limits (QT Ls) will be predefined in the sponsor risk management plan  
to identify systematic issues that can impact subject  safety and/or reliability of trial 
results. These predefined QTLs  will be monitored during the trial, and important 
deviations from the QTLs and remedial actions taken will be summarized in the clinical 
trial report.  
• Monitoring details describing strategy , including definition of trial critical data items and 
processes (e.g., risk -based initiatives in op erations and quality such as risk management 
and mitigation strategies and analytical risk-based monitoring), methods, responsibilities , 
and requirements, including handling of noncompliance issues and monitoring techniques 
(central, remote, or on -site mon itoring) are provided in the monitoring plan.  
• The sponsor or designee is responsible for the data management of this trial, including 
quality checking of the data.  
• The sponsor assumes accountability for actions delegated to other individuals ( e.g., 
contrac t research organizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this trial 
must be retained by [CONTACT_1732] 25 years after trial completion unless local 
regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the sponsor. No 
records may be transferred to another location or part y without written notification to the 
sponsor.  
10.1.8.  Source Documents  
• Source documents containing source data provide evidence for the existence of the 
subject  and substantiate the integrity of the data collected. Source documents are filed at 
the investigator’s  site. 
• Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
CONFIDENTIAL  VP-C21-[ADDRESS_312331] be available.  
• Definition of what constitutes source data and its origin can be found in the monitoring 
manual.  
• The investigator must maintain accurate documentation (source data) that sup ports the 
information entered in the CRF.  
• Trial  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of subject s are being protected; and that the 
trial is being conducted in accordance with the currently approved protocol and any other 
trial agreements, ICH GCP, and all applicable regulatory requirements.  
10.1.9.  Trial  and Site Start and Closure  
First Act  of Recruitment  
The trial start date is the date on which the clinical trial will be open for recruitment of subject s. 
The first act of recruitment is the first site open  and will be the trial start date.  
Trial /Site Termination  
The sponsor or designee reserves the right to close the trial site or terminate the trial at any time 
for any reason at the sole discretion of the sponsor. Trial  sites will be closed upon trial 
completion. A trial site is considered closed when all required documents and  trial supplies have 
been collected and a trial-site closure visit has been performed.  
The investigator may initiate trial-site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a trial site by [CONTACT_66892]:  
For trial termination:  
• Discontinuation of further IMP development . 
For site termination:  
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the sponsor ’s procedures, or GCP guidelines . 
• Inadequate  or no  recruitment  (evaluated after a reasonable amount of time)  of subject s by 
[CONTACT_093] . 
• Total number of subject s included earlier than expected . 
If the trial is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the trial of the reason f or termination or suspension, as specified by [CONTACT_11005]. The investigator shall promptly inform the subject  and should assure 
appropriate subject  therapy and/or follow -up. 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 51 of 77 Vicore Pharma AB   
10.1.10.  Publication Policy  
• The primary publication should be p ublished  by [CONTACT_256998] -initiated  publications, manuscripts, abstracts,  or presentations.  
• The results of this trial may be published or presented at scientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor 
before submission. This allows the sponsor to protect proprietary information and to 
provide comments.  
• The sponsor will comply with the requirements for publication of trial results. In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publication of multicenter studies only in their entirety and not as individual site data. In 
this case, a coordinating investigator [INVESTIGATOR_12992].  
• Authorship will be determined by [CONTACT_14346].  
  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 52 of 77 Vicore Pharma AB  10.2. Appendix 2: AEs  and SAEs : Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
10.2.1.  Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a clinical trial subject , temporally 
associated with the use of IMP, whether or not considered related to the IMP. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of IMP. 
 
Events Meeting the AE Definition  
• Any abnormal laboratory test results ( hematology , clinical chemistry, or urinalysis) or 
other safety assessments ( e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investigator ( i.e., not related to progression of 
underlying disease) . 
• Exacerbation of a chronic or intermittent pre -existing condition including eit her an 
increase in frequency and/or intensity of the condition . 
• New condition detected or diagnosed after IMP administration even though it may 
have been present before the start of the trial. 
• Signs, symptoms, or the clinical sequelae of a suspected interv ention -intervention 
interaction . 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either IMP or a 
concomitant therapy . Overdose to be reported as an AE/SAE .  
• Lack of efficacy or failure of expected pharmacological action per se will not  be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfill the definition of an AE or SAE.  
Events NOT  Meeting the AE D efinition  
• Medical or surgical procedure ( e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE . 
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]) . 
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the trial that do not worsen . 
CONFIDENTIAL  VP-C21-[ADDRESS_312332] medical occurrence  that, at any dose , meets one  or 
more  of the criteria liste d: 
a. Results in death  
b. Is life  threatening  
The term life threatening  in the definition of serious  refers to an event in which the subject  
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_1081]  
• In general, hospi[INVESTIGATOR_256974]  (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_256975]/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether hospi[INVESTIGATOR_51956], the 
AE should be considered serious.  
• Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent  or significant  disability/incapacity  
• The term disability means a substantial  disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma  (e.g., sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption . 
e. Is a congenital anomaly/birth defect  
f. Other situations:  
• Medical or scientific judgment should be exercised by [CONTACT_256999]. These events should 
usually be considered serious.  
o Examples of such events include invasive or malignant cancers, intensive 
treatment for allergic bronchospasm, blood dyscrasias , convulsio ns or 
development of intervention  dependency or intervention  abuse . 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 54 of 77 Vicore Pharma AB  10.2.3.  Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
• AEs will be collected from signing the ICF . AEs occurring after first IMP intake will be 
considered treatment -emergent adverse events (TEAEs ) in the statistical analysis . 
• A pre-existing medical condition should be reported as an adverse event if the condition 
increases in severity (e.g. from mild to moderate ).  
• At each visit the subject should  be asked about AEs in an objective manner, e.g.: “Have 
you experienced any problems since the last visit?” . 
• Only medically qualified personnel ( investigators) must assess AEs.  
• When an AE/SAE occurs , it is the responsibility of the investigator to review all 
documentation ( e.g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics 
reports) related to the event.  
• The investigator will then record all relevant AE/SAE information . 
• It is not accep table for the investigator to send photocopi[INVESTIGATOR_9238] ’s medical 
records to the sponsor or designee in lieu of completion of the SAE form . 
• There may be instances when copi[INVESTIGATOR_61499] . In this case, all subject  identifiers, with the exception of the 
subject  number, will be redacted on the copi[INVESTIGATOR_61500] . 
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE . 
• All AEs should be followed until they have reach ed a final outcome 
(Recovered/resolved , recovering/  resolving , recovered/resolved with sequelae ) or the 
subject’s participation in the trial ends, whichever comes first .  
• SAEs and non -serious AEs considered related to IMP treatment  should be followed on 
a regular basis according to the investigator’s clinical judgment until a final outcome 
has been established.   
• The outcome “recovering” can be used as the final outcome for events that are 
stabilized (in essence no fu rther worsening is expected ) and expected by [CONTACT_257000] .  
The outcome “not resolved” can be used as the final outcome for events that are not 
expected to resolve over time (e.g. cancer) . 
 
 
 
 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 55 of 77 Vicore Pharma AB  Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the trial and assign it to one of the following categories:  
• Mild:  Awareness of symptoms, sign, illness, or event that is easily tolerated . 
• Moderate: Discomfort  sufficient to interfere with usual activities . 
• Severe: Incapacitating with inability to work or undertake further normal activiti es. 
Note the distinction between seriousness and severity: The term severe is used to de scribe the 
intensity of the event and a severe event is not necessarily serious. A severe headache would 
probably not constitute a SAE whilst a mild myocardial infarction likely would constitute a 
SAE. The seriousness criteria serve as a guide for defining  regulatory reporting obligations.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between IMP and each 
occurrence of each AE/SAE . The investigator will use clinical judgment to determine 
the relationship.  
• A reasonable possibility  of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out. 
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to IMP administration , will be 
considered and investigated.  
• The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.  
• There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to sponsor or designee . However, it 
is very important that the investigator always make s an assessment of causality for 
every event bef ore the initial transmission of the SAE data to sponsor or designee . 
• The investigator may change his/her opi[INVESTIGATOR_256976] -up 
information is available  and send an SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
• The relationship will be characterized using the following causality ratings:  
o Related : There is a reasonable possibility that the AE was caused by [CONTACT_257001] . There is a reasonable time relationship to IMP treatment intake. The 
AE cannot be explained by [CONTACT_19699]. There may or may not be 
information about de -challenge o r re-challenge. Disappearance of the AE upon 
de-challenge supports this category. Reappearance upon re -challenge is 
strongly supportive.  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 56 of 77 Vicore Pharma AB  o Not related : There is no reasonable possibility that the event was caused by [CONTACT_86184]. The temporal relationship to drug  administration makes a causal 
relationship improbable or other drugs or underlying disease or conditions 
provide plausible explanations.  
o Not applicable : This assessment can be used e.g., in cases where the subject  did 
not receive any treatment with IMP  
Outcome  
The Investigator is obliged to record the most appropriate outcome using the following  categories : 
• Recovered/resolved  
• Recovering/resolving  
• Not recovered/not resolved/ongoing  
• Recovered/resolved with sequelae  
• Fatal  
• Unknown  
Follow -up of AEs and SAEs  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_11011]/or causality of the AE or SAE as fully as possible . 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
• The investigator will submit any updated SAE data to sponsor or designee  within 24 
hours of receipt of t he information.  
10.2.4.  Reporting of SAEs  
SAE Reporting to the sponsor or designee  via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to  the sponsor or designee  will be the 
electronic data collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• After the trial is completed at a given site, the electronic data collection tool will be 
taken offline to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a trial subject  or receives updated data on 
a previously reported SAE after the electronic data collection tool has been taken 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 57 of 77 Vicore Pharma AB  offline, then the site can report this information on a paper SAE form or to the sponsor 
or designee  by [CONTACT_756].  
• Contacts for SAE reporting can be found in the Safety Management Plan provided to 
the sites . 
  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 58 of 77 Vicore Pharma AB  10.3. Appendix 3: Contraceptive and Barrier Guidance  
10.3.1.  Requirements  
Contraceptive use by [CONTACT_257002]:  
1. Male subject s are eligible to participate if they agree to the following during the IMP 
treatment period and for at least [ADDRESS_312333] dose of IMP: 
i. Refrain from donating fresh unwashed semen  
AND  
ii. Must agree to use contraception /barrier as detailed below  
iii. Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highly effective method of contraception as a condom 
may break or leak when having sexual intercourse with a woman ) of 
childbearing potential  (WOCBP)  who is not cu rrently pregnant  
iv. Agree to use a male condom when engaging in any activity that allows for 
passage of ejaculate to another person  
 
2. Female subjects are eligible to participate if she is not pregnant or breast feeding , and the 
following conditions applies:  
i. Is a woman of nonchildbearing potential (WONCBP) as defined in section  
10.3.2 . Contraception and Barrier Guidance.  
ii. Is a WOCBP and using a contraceptive method that is highly effective (with a 
failure rate of <1% per year), preferably  with low user dependency . 
Contraception and Barrier Guidance during the IMP treatment period and for 
at least [ADDRESS_312334] dose of IMP and agrees not to donate eggs (ova, 
oocytes) for the purpose of reproduction during this period. The investigator 
should evaluate the potential for contraceptive method failure ( e.g., 
noncompliance, recently initiated) in relationship to the first dose of  IMP. 
iii. A WOCBP must have a negative highly sensitive pregnancy test ( urine  or 
serum ) as required by [CONTACT_427]) before the first dose of IMP (see 
Section 0). 
iv. If a urine test cannot be confirmed as negative ( e.g., an ambiguous result), a 
serum pregnancy test is required. In such cases, the subject  must be excluded 
from participation if the serum pregnancy result is positive.  
v. Additional requirem ents for pregnancy testing during and after IMP treatment 
(see Section  8.5.5 ). 
vi. The investigator is responsible for review of medical history, menstrual 
history, and recent sexual activity to decrease the risk for inclusion of a 
woman with an early undetected pregnancy . 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 59 of 77 Vicore Pharma AB  10.3.2.  Definitions  
Women in the following categories are considered WOCBP (fertile):  
• Following menarche  
• From the time of menarche until becoming postmenopausal unless permanently sterile 
(see below)  
• Permanent sterilization methods (for the purpose of this trial) include:  
o Documented hysterectomy  
o Documented bilateral salpi[INVESTIGATOR_1656]  
o Documented bilateral oophorectomy  
o For individuals with permanent infertility due to an alternate medical cause other than 
the above, ( e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), 
investigator discretion should be applied to determining trial entry.  
Note:  Documentation can come from the site personnel’s review of the subject ’s medical 
records, medical e xamination, or medical history interview.  
• If fertility is unclear ( e.g., amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before first dose of IMP treatment , additional evaluation should be 
considered.  
Women in the following  categories are considered WONCBP:  
• Premenopausal female with permanent infertility due to one of the following:  
a. Documented hysterectomy  
b. Documented bilateral salpi[INVESTIGATOR_1656]  
c. Documented bilateral oophorectomy  
d. For individuals with permanent infertility due to a n alternate medical cause other 
than the above, ( e.g., Mullerian agenesis, androgen insensitivity, gonadal 
dysgenesis), investigator discretion should be applied to determining trial 
eligibility . 
Note : Documentation can come from the site personnel’s review of the subject ’s medical 
records, medical examination, or medical history interview.  
• Postmenopausal female  
a. A postmenopausal state is defined as no menses for 12 months without an 
alternative medical  cause.  
i. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using 
hormonal contraception or hormonal replacement therapy (HRT). 
However, in the absence of 12 months of ameno rrhea, confirmation with 
more than one FSH measurement is required.  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 60 of 77 Vicore Pharma AB  Females on HRT and whose menopausal status is in doubt  should not be 
considered to be in a postmenopausal state.  
10.3.3.  Contraception Guidance  
CONTRACEPTIVESa ALLOWED DURING THE TRIAL INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulationc 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS )c 
• Bilateral tubal occlusion  
• Azoospermic partner (vasectomized or due to a medical cause)  
Azoospermia is a highly effective contraceptive method provided that the partner is the sole sexual partner 
of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used. Spermatogenesis cycle is approximately 90 days.  
Note: documentation of azoospermia for a male subject  can come from the site personnel’s rev iew of the 
subject ’s medical records, medical examination, or medical history interview.  
Highly Effective Methodsb That Are User Dependent  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition of 
ovulationc 
o oral 
o intravaginal  
o transdermal  
o injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulationc 
o oral 
o injectable  
a) Contraceptive use by [CONTACT_103092].  
b) Failure rate of <1% per year when used consistently and correctly.  Typi[INVESTIGATOR_17964].  
c) If locally required, in accordance  with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
contraceptive methods are limited to those which inhibit ovulation as the primary mode of action.  
Note: Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception for 
this trial. Male condom and female condom should not be used together (due to risk of failure from friction).  
 
 
  
CONFIDENTIAL  VP-C21-[ADDRESS_312335] of Care  for COVID -19 
 
All subjects receiving IMP will also receive SoC for COVID -19, which may include:  
• Oxygen administration to maintain oxygen saturation of 90 %  to 96 % , including 
suppl emental oxygen  (low flow or high flow) , non-invasive  or invasive  mechanical 
ventilation  or ECMO  
• Frequent clinical assessment s of neurological, pulmonary, cardiac, gastrointestinal,  and 
urinary status as required depending on clinical status  
• At least daily m onitoring of vital signs ( heart rate, blood pressure, body temperature , 
respi[INVESTIGATOR_14367] (SpO 2))  
• Telemetry monitoring to evaluate hearth rhythm and rate  
• Diet as tolerated to satisfy nutritional needs  
• Mobilization of the subject  and rotation to prone positioning of ventilated subjects  
• Treatment for COVID -19 symptoms including antibiotics, cough suppressant / 
expectorants, anti -coagulants, analgesics, antipyretics , antiemetics and/or 
bronchodilators ; refer also to section 6.8 regarding permitted prior o r con current therapy  
• Treatment s for COVID -19 which are: Administered in accordance with approved 
conditions by [CONTACT_257003]  (Specific for India ; Indian Council for 
Medical Research ( ICMR ) guidelines for management of COVID -19 patients  (ICMR, 
2021 )), including emergency use authorization s, conditional approval s, or article 5(3) 
reviews,  
 
AND   
 
• Approv ed under such conditions in the US or EU, and/or recommended in international 
consensus guidelines (e.g., remdesivir, dexamethasone, tocilizumab, convalescent 
plasma , and certain monoclonal antibodies ). See section 6.8 regarding pe rmitted prior or 
concurrent therapy .  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 62 of 77 Vicore Pharma AB  10.5. Appendix 5: Country -specific Requirements  
 
10.5.1.  India  
The trial will be a phase 2/3 trial. 80 subjects will be enrolled from India in the phase 2 part of 
the trial.   
Protocol title: A randomized, double -blind, placebo -controlled,  parallel group,  phase  2/3, 
multicenter  trial investigating the efficacy and safety of  C21 as add on to standard of 
care in adult subjects  with COVID -19. 
Inclusion criteri on 1: Age ≥18 at the time of signing the informed consent , to ≤65 years . 
 
Inclusion criterion 7: Specific for India : For subjects with an ordinal scale score of 5 , moderate to 
severe COVID -19 disease confirmed by [CONTACT_256986] 2 ≤ 93 % or a respi[INVESTIGATOR_697] ≥ 24/min on 
room air. Note: If a subject  is on supplemental oxygen with SpO2 >93% and respi[INVESTIGATOR_697] 
<24/min , but desaturation to ≤ 93 % or increase of respi[INVESTIGATOR_80753] ≥ 24/min on lower 
supplemental oxygen or room air is documented during screening, the inclusion criterion is 
considered to be met. 
 
Standard of Care for COVID -19 include s the ICMR guidelines for management of COVID -19 
patients  (ICMR, 2021 ) (ICMR, 2021 ).  
 
 
 
  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 63 of 77 Vicore Pharma AB  10.6. Appendix 6: Abbreviations  
ACE  Angiotensin Converting Enzyme  
AE Adverse Event 
ANCOVA  Analysis of covariance  
ALT  Alanine  Transferase  
ALP  Alka line Phosphatase  
AST  Aspartate Aminotransferase  
AT1R  Angiotensin II type [ADDRESS_312336] Cancer Resistance Protein  
b.i.d. bis in die (i.e. twice a day)  
BUN  Blood Urea Nitrogen  
CFR  Code of Federal Regulation  
COVID -19 Corona Virus Disease 2019  
CYP  Cytochrome P450  
CYP1A2  Cytochrome P450 Family 1 Subfamily A Member 2  
CYP2C9  Cytochrome P450 Family 2 Subfamily C Member 9  
CYP3A4  Cytochrome P450 Family 3 Subfamily A Member 4  
DMC Data Monitoring Committee  
ECMO  Extra  Corpor eal Membrane Oxygenation  
ECG  Electrocardiogram  
eGFR  estimated Glomerular Filtration Rate  
EWD  Early Withdrawal  
FiO 2 Fraction of inspi[INVESTIGATOR_256977]-C21-008 Version 5.0 
 
13-Apr-2022  Page 64 of 77 Vicore Pharma AB  HIV  Human Immunodeficiency Virus  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonization  
ICMR  Indian Council for Medical Research  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
IMP Investigational Medicinal Product  
LDH  Lactate Dehydrogenase  
MCV  Mean Corpuscular Volume  
MDR1  
MedDRA  Multi Drug Resistance [ADDRESS_312337] version   
Amendment 1 to 
the protocol.  
Non-substantial.  
Final protocol, 
version 2.0, 
dated 06-May-
2021 . Section 2.2. Background  
Statistical conclusion on 
the primary endpoint in the 
phase 2 trial added.  Sentence added to provide more 
clarity.  
 
Section 5.2 Exclusion 
Criteria  
Exclusion criterion: 
Impaired hepatic function 
(i.e., Child -Pugh class A or 
B) changed to Impaired 
hepatic function ( i.e., 
Child -Pugh class B or C ). Correction of error in the exclusion 
criterion.  
 
Section 9.3.[ADDRESS_312338].  and alignment 
with interim analysis plan.   
Section 3 Objectives, 
Endpoints, and Estimands  Endpoint added to include a lung 
injury biomarker.  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 67 of 77 Vicore Pharma AB   Endpoint, change in LDH 
added.   
 Section 4.2. Scientific 
rationale for Trial Design  
Description of individual 
change in ordinal scale 
score s reflected in the 
primary endpoint added.  Additional clarification of the 
primary endpoint.  
 Section 5.1 Inclusion 
Criteria  
Indian specific ; Age limits 
and SpO [ADDRESS_312339].  
 SpO2 / FiO2 ratio added to 
exclusion criterion 9.  Added if a blood gas test is not 
available.  
 Section 6.[ADDRESS_312340].  
9.4 Interim Analysis  
Additional details on the 
interim analysis provided 
including a cap of 450 
subjects per. treatment arm.  Additional clarifications on the 
interim analysis.  
[IP_ADDRESS]. Data monitoring 
committee  
Option for a third DMC 
meeting added.  Per authority request.  
 
 
 
 
 
 
 10.3 Appendix 3: 
Contraceptive and Barrier 
Guidance  
Abstinence removed.  Per authority request.  
10.3.[ADDRESS_312341].  
Section 10.5 Appendix 5: 
Country -specific 
Requirements for India  
added.  Per authority request.  
  
Amendment [ADDRESS_312342] details for 24/7 
medical coverage  In accordance with the information  
already  distributed to the sites.  
Final protocol, 
Version 4.0, 
dated 07-Dec-
2021.  Section 1.3 Schedule of 
Activities  Added possibility to use local lab for 
analysis of safety samples  in special 
circumstances . 
 Section 5.1 Inclusion 
criteria  
Added “hospi[INVESTIGATOR_307] -approved 
diagnostic ” PCR test  to 
inclusion criterion 2. Per authority request.   
 
 
 
 Section 5.2 Exclusion 
criteria   
Exclusion criterion 3 
rephrased to clarify that  the 
alterations in the Child -
Pugh score are caused by 
[CONTACT_257004] , 
not another underlying 
disease.  Clarification of  the severity 
assessment of hepatic impairment . 
 
Section 5.2 Exclusion 
criteria  
Exclusion criterion 5 
changed to a COVID -19 
symptom onset >21 days 
prior to screening (Visit 1).   
To align with new evidence 
suggest ing that subjects infected 
with SARS -CoV -[ADDRESS_312343] a longer duration of illness  
(Antonelli et al., 2021 ).  
CONFIDENTIAL  VP-C21-[ADDRESS_312344].  
Amendment 4 to 
protocol.  
Substantial.  
Final protocol, 
Version 5.0, 
dated 13-Apr-
2022. Overall changes (all 
changes were implemented 
without access to 
unblinded data from the 
ongoing trial):  
The   primary endpoint has 
been changed from 
proportion of subj ects 
discharged from hospi[INVESTIGATOR_256978] [ADDRESS_312345] . 
 
 
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 74 of 77 Vicore Pharma AB  12. References  
Akishita, M., Ito, M., Lehtonen, J. Y., Daviet, L., Dzau, V. J., & Horiuchi, M. (1999). Expression 
of the AT2 receptor developmentally programs extracellular signal -regulated kinase 
activity and influences fetal vascular growth. J Clin Invest , 103(1), 63 -71. 
https://doi.org/10.1172/JCI5182   
Antonelli, M., Penfold, R. S., Merino, J., Sudre, C. H., Molteni, E., Berry, S., Canas, L. S., 
Graham, M. S., Klaser, K., Modat, M., Murray, B., Kerfoot, E., Chen, L., Deng, J., 
Osterdahl, M. F., Cheetham, N. J., Drew, D. A., Nguyen, L. H., Pujol, J. C., . . . Steves, 
C. J. (2021). Risk factors and disease profile of post -vaccination SARS -CoV -2 infection 
in [LOCATION_006] users of the COVID Symptom Study app: a prospective, community -based, nested, 
case-control study. Lancet Infect Dis. https://doi.org/10.1016/S1473 -3099(21)[ZIP_CODE] -6  
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., 
Hohmann, E., Chu, H.  Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. 
W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., 
Short, W. R., . . . Members, A. -S. G. (2020). Remdesivir for the Treatment of Covid -19 - 
Final Repor t. N Engl J Med , 383(19), 1813 -1826. 
https://doi.org/10.1056/NEJMoa2007764   
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y.,  
Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epi[INVESTIGATOR_98188] 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a 
descriptive study. Lancet , 395([ZIP_CODE]), 507 -513. https://doi.org/10.1016/S0140 -
6736(20)[ZIP_CODE] -7  
De Gasparo, M. (2002). [AT(1) and AT(2) angiotensin II receptors: key features]. Drugs , 62 
Spec No 1 , 1-10. https://www.ncbi.nlm.nih.gov/pubmed/12036384  (Les recepteurs AT(1 
) et AT(2 ) de l'angiotensine II: l'essentiel.)  
de Man, F. S., Tu, L., Handoko, M. L., Rain, S., Ruiter, G., Francois, C., Schalij, I., Dorfmuller, 
P., Simonneau, G., Fadel, E., Perros, F., Boonstra, A., Postmus, P. E., van der Velden, J., 
Vonk -Noordegraaf, A., Humbert, M., Eddahibi, S., & Guignabert, C. (2012). 
Dysregulated renin -angiotensin -aldosterone system contributes to pulmonary arterial 
hypert ension. Am J Respir Crit Care Med , 186(8), 780 -789. 
https://doi.org/10.1164/rccm.201203 -0411OC   
Dodd, L. E., Follmann, D., Wang, J., Koenig, F., Korn, L. L., Schoe rgenhofer, C., Proschan, M., 
Hunsberger, S., Bonnett, T., Makowski, M., Belhadi, D., Wang, Y., Cao, B., Mentre, F., 
& Jaki, T. (2020). Endpoints for randomized controlled clinical trials for COVID -19 
treatments. Clin Trials , 17(5), 472 -482. https://doi.org/10.1177/1740774520939938   
FDA. (2003). Guidance for Industry - Pharmacokinetics in Patients with Impaired Hepatic 
Function: Study Design Data Analysis, and Impact on  Dosing and Labeling .  Retrieved 
from https://www.fda.gov/media/[ZIP_CODE]/download  
FDA. (2009). Guidance for Industry Drug -Induced Liver Injury: Premarketing Clinical 
Evaluation.  
FDA. (2020a). COVID -19: Developi[INVESTIGATOR_135312] - Guidance for Industry  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 75 of 77 Vicore Pharma AB  FDA. (2020b). Drug development and drug interactions. Table of substrates, inhibitors and 
inducers .  
Ge, M., Durham, L. K., Meyer, R. D., & Thomas, N. (2011). Covariate -Adjusted Difference in 
Proportions from Clinical Trials Using Logistic Regression and W eighted Risk 
Differences. Ther. Innov. Regul. Sci. , 45, [ADDRESS_312346], S. N., . . . Landray, M. J. 
(2020). Dexamethasone in Hospi[INVESTIGATOR_61013] -19 - Preliminary Report. N 
Engl J Med . https://doi.org/10.1056/N EJMoa2021436   
ICMR. (2021). CLINICAL GUIDANCE FOR MANAGEMENT OF ADULT COVID -19 
PATIENTS.  
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, 
Y., Ma, X., Zhan, F., Wang, L., Hu , T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., . . . Tan, 
W. (2020). Genomic characterisation and epi[INVESTIGATOR_14849] 2019 novel coronavirus: 
implications for virus origins and receptor binding. Lancet , 395([ZIP_CODE]), 565 -574. 
https://doi.org/10.1016/S0140 -6736(20)[ZIP_CODE] -8  
Marconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., Pi[INVESTIGATOR_256979], 
M. L. B., Goldman, J. D., Alatorre -Alexander, J., de Cassi a Pellegrini, R., Estrada, V., 
Som, M., Cardoso, A., Chakladar, S., Crowe, B., Reis, P., Zhang, X., Adams, D. H., Ely, 
E. W., & Group, C. -B. S. (2021). Efficacy and safety of baricitinib for the treatment of 
hospi[INVESTIGATOR_256980] -19 (COV -BARRIER):  a randomised, double -blind, 
parallel -group, placebo -controlled phase 3 trial. Lancet Respir Med , 9(12), 1407 -1418. 
https://doi.org/10.1016/S2213 -2600(21)[ZIP_CODE] -3  
Matavelli, L. C., Zatz, R., & Siragy, H. M. (2015). A nonpeptide angiotensin II type [ADDRESS_312347] prevents renal inflammation in early diabetes. J Cardiovasc Pharmacol , 65(4), 
371-376. https://doi.org/10.1097/FJC.0000000000000207   
Protein -Atlas. The Human Protein Atlas . https://www.proteinatlas.org/ENSG00000180772 -
AGTR2  
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Clinical predictors of mortality due 
to COVID -19 based on an analysis of data of 150 patients from Wuhan, China. Intensive 
Care Med , 46(5), 846 -848. https://doi.org/10.1007/s00134 -020-[ZIP_CODE] -x  
Savoia, C., & Schiffrin, E. L. (2006). Inhibition of the renin angiotensin system: implications for 
the endothelium. Curr Diab Rep , 6(4), 274 -278. https://doi.org/10.1007/s11892 -006-
0060 -5  
Shah, A. S., Wong, A. W., Hague, C. J., Murphy, D. T., Johnston, J. C., Ryerson, C. J., & 
Carlsten, C. (202 1). A prospective study of 12 -week respi[INVESTIGATOR_256981] -19-
related hospi[INVESTIGATOR_56183]. Thorax , 76(4), 402 -404. https://doi.org/10.1136/thoraxjnl -2020 -
216308   
Steckelings, U. M., Kaschina, E., & Unger, T. (2005). The AT2 receptor --a matter of love and 
hate. Peptides , 26(8), 1401 -1409. https://doi.org/10.1016/j.peptides.2005.03.[ADDRESS_312348], A. H., Bertelsen, J. B., & Steckelings, U. M. (2019). Anti -
fibrotic mechanisms of angiotensin AT2 -receptor stimulation. Acta Physiol (Oxf) , 
227(1), e13280. https://doi.org/10.1111/apha.[ZIP_CODE]   
Szekely, L., Bozoky, B., Bendek, M., Ostad, M., Lavignasse, P., & Haag, L. (2020). Pulmonary 
stromal expansion and intra -alveolar coagulation are primary causes of Covid -19 de ath. . 
bioRxiv . https://doi.org/10.1101/2020.12.23.424172 .  
Tan, C., Huang, Y., Shi, F., Tan, K., Ma, Q., Chen, Y., Jiang, X., & Li, X. (2020). C -reactive 
protein c orrelates with computed tomographic findings and predicts severe COVID -19 
early. J Med Virol , 92(7), 856 -862. https://doi.org/10.1002/jmv.[ZIP_CODE]   
Voshaar, T., Stais, P., Koh ler, D., & Dellweg, D. (2021). Conservative management of COVID -
19 associated hypoxaemia. ERJ Open Res , 7(1). https://doi.org/10.1183/23120541.[ZIP_CODE] -
2021   
Wang, L. (2020). C -reactive protein levels in the early stage of COVID -19. Med Mal Infect , 
50(4), 332 -334. https://doi.org/10.1016/j.medmal.2020.03.007   
WHO. (202 0a). A coordinated global research roadmap: 2019 novel coronavairus . 
https://www.who.int/emergencies/diseases/novel -coronavirus -2019  
WHO. (2020 b). COVID -19 Therapeutic Trial Synopsis . https://www.who.int/blueprint/priority -
diseases/key -action/COVID -
19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf  
Wu, P., Hao, X., Lau, E. H. Y., Wong, J. Y., Leung, K. S. M., Wu, J. T., Cowling, B. J., & 
Leung, G. M. (2020). Real -time tentative assessment of the ep idemiological 
characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. 
Euro Surveill , 25(3). https://doi.org/10.2807/1560 -7917.ES.2020.25.3.2000044   
Xie, J., Covassin, N., Fan, Z., Singh, P., Gao, W., Li, G., Kara, T., & Somers, V. K. (2020). 
Association Between Hypoxemia and Mortality in Patients With COVID -19. Mayo Clin 
Proc , 95(6), 1138 -1147. https://doi.org/10.1016/j.mayocp.2020.04.006   
Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin -converting 
enzyme 2 (ACE2) as a SARS -CoV -2 receptor: molec ular mechanisms and potential 
therapeutic target. Intensive Care Med , 46(4), 586 -590. https://doi.org/10.1007/s00134 -
020-[ZIP_CODE] -9  
Zhou, P., Yang, X. L., Wang, X. G ., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., 
Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. D., Liu, M. Q., Chen, Y., 
Shen, X. R., Wang, X., . . . Shi, Z. L. (2020). A pneumonia outbreak associated with a 
new coronavirus o f probable bat origin. Nature , 579(7798), 270 -273. 
https://doi.org/10.1038/s41586 -020-2012 -7  
 
  
CONFIDENTIAL  VP-C21-008 Version 5.0 
 
13-Apr-2022  Page 77 of 77 Vicore Pharma AB  13. Sponsor and Coordinating Investigator [INVESTIGATOR_7496] s  
 
Vicore Pharma  
  
Chief Medical Officer   
Rohit Batta, MBBS , MRCGP , FFPM  
     
  Signature   [CONTACT_257006], Clinical Development  
Elin Rosendahl , M.Sc.  
     
  Signature  
  [CONTACT_257007], M.Sc .   
Statmind AB      
  Signature   [CONTACT_257008]  
[INVESTIGATOR_93373]. Maureen Horton, M.D.  
Johns Hopkins University School of 
Medicine , Baltimore, [LOCATION_003]      
  Signature   [CONTACT_1782]  
 
 